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Alloimmune hemolytic anemia of the fetus and newborn
A woman, negative for a red cell antigen, may produce antibodies when 
she comes into contact with erythrocytes positive for the offending antigen 
either by blood transfusion, an organ transplant, or as a consequence 
of a fetomaternal transfusion. In a pregnant woman, IgG antibodies 
will cross the placenta leading to hemolysis in the fetus and more or 
less severe fetal anemia. This process is often called erythroblastosis 
fetalis and consequences include intrauterine demise and neonatal 
hyperbilirubinaemiae, eventually leading to kernicterus with its 
concomitant morbidity and mortality.
In 1940, Landsteiner and Weiner discovered the clinically most important 
red cell antigen, the “rhesus factor” through their research with Macacus 
rhesus, a monkey species.1 In the following decades, doctors learned to 
understand the pathogenesis of alloimmune hemolytic anemia, found 
ways to diagnose and treat the condition and even discovered how to 
effectively prevent the disease. It was a success story in medicine and at the 
same time it was the start of a new subspecialty: fetal medicine. 
Prevention
Hemolytic disease of the newborn was once a major contributor to 
perinatal morbidity and mortality. During the past 4 decades, there 
has been a remarkable improve of fetal outcome, due to the improved 
neonatal care, the introduction of intrauterine transfusion, and the 
introduction of prevention with anti-D. Administration of anti-D to 
a rhesus-negative mother after the birth of a rhesus-positive child 
leads to decreased immunization rates. However, in some cases, 
rhesus immunization will already have occurred (during pregnancy) 
or the amount of anti-D may not sufﬁce in cases of large fetomaternal 
transfusions. Blood transfusions and organ (kidney, bone) transplant are 
other possible causes of alloimmunization. Finally, maternal non-rhesus D 
red blood cell antibodies may also lead to fetal alloimmune anemia.
CHAPTER 1 |  General introduction
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Screening
In the Netherlands, there is a nationwide screening policy since 1998. 
All pregnant women are tested in the ﬁrst trimester of pregnancy for the 
presence of red cell antibodies. Screen-positive women are categorized 
as no-risk, low-risk or high-risk for fetal anemia according to the 
type of antigen and the concentration of antibodies. In case of high 
antibody titers, the Antibody Dependent Cell Cytotoxicity (ADCC) test is 
performed.2 Pregnancies at high risk for fetal anemia, for example in case 
of anti-D antibodies with an indirect Coombs titer of >1/32 and an ADCC 
test of >50% are referred to Leiden University Medical Center (LUMC). 
Diagnosis
When a woman is referred to LUMC the obstetrical history is taken 
into account. Further, ADCC tests and antibody titers are followed. 
The women are instructed to pay special attention to fetal movements. 
Ultrasound examinations are performed: depending on the severity of 
the immunization, weekly or bi-weekly. The ultrasound examination 
is focussed on fetal movements, early signs of hydrops, fetal liver and 
spleen enlargement, cor-thorax ratio, umbilical vein maximum ﬂow 
and middle cerebral artery peak ﬂow measurement. In case of a severe 
immunization and inconclusive ultrasound ﬁndings, amniocentesis 
and bilirubin concentration measurement is performed. Bilirubin is the 
main degradation product of hemoglobin and therefore a measure of 
its destruction. Bilirubin concentration in amniotic ﬂuid is measured 
colorimetrically by performing a spectral absorption curve. The bilirubin 
absorption, expressed as Δ OD 450 is calculated as the difference between 
the measured light absorption at 450 nm and the background absorption 
at 450 nm.3 If then there is suspicion of severe anemia, fetal blood 
examination and an intrauterine transfusion is performed. 
Therapy
In case of a less advanced pregnancy the therapy of choice of fetal anemia 
is intrauterine blood transfusion. At LUMC intrauterine transfusions 
are performed as early as 16 weeks of gestation and repeat transfusions 
are given every 2-4 weeks up to 35 weeks,4;5 aiming that women give 
birth between 36 and 38 weeks of gestation. After birth, phototherapy, 
transfusions and/or exchange transfusions may be necessary.
Despite its undoubted merits, an intrauterine transfusion is not without 
risk. Procedure-related fetal loss rates are in the range of 1-3% per 
procedure.4;5 Furthermore, every intrauterine transfusion carries the 
risk of fetomaternal hemorrhage, which may increase the severity of 
alloimmunization. A signiﬁcant increase in antibody concentration occurs 
in 50% of cases after intrauterine transfusion.6
National strategy in the Netherlands
In the Netherlands all pregnant women have a blood test taken for 
irregular antibodies in the ﬁrst trimester of pregnancy. In case of a 
rhesus negative mother without irregular antibodies the blood test 
will be repeated at 30 weeks and the mother will receive anti-D. In the 
Netherlands we have approximately 200 pregnancies yearly with new cases 
of potentially dangerous red cell antibodies. (170 anti-D, approximately 
30 anti-K and anti-c). Of these, approximately 100 pregnant women 
a year will have high antibody titers. In the Netherlands, care for fetal 
alloimmunization is centralised and all severely immunized pregnancies are 
referred to the LUMC. In the LUMC, pregnant women with high antibody 
titers are followed with ultrasound examinations and, if deemed necessary, 
amniocentesis, until, in approximately 1/3 of them, suspicion of severe 
fetal anemia leads to the performance of an intrauterine transfusion. 
Yearly, around 100 intrauterine transfusions in approximately 30 fetuses 
are performed. 
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Outline of the thesis
This thesis is about the physiological basis and the diagnostic accuracy of 
two methods to asses the severity of fetal hemolytic anemia: measurement 
of bilirubin concentration in amniotic ﬂuid on the one hand and fetal 
ultrasound on the other hand.
Part 1: Chemical approach
Since the 1960s, Δ OD 450 measurements have been the main diagnostic 
procedure for prediction of fetal anemia and since the 1990s, the Doppler 
technique is upcoming. We performed a Medline search (chapter 2) to 
compare those two diagnostic tools.
The Δ OD 450 technique has been shown to have good diagnostic 
qualities from 27 to 36 weeks of pregnancy. In chapter 3, we assessed the 
diagnostic accuracy of amniotic ﬂuid Δ OD 450 in our patient population 
from 18 weeks onwards. 
It is still unknown how bilirubin enters the amniotic ﬂuid. We studied 
(chapter 4) the relationship between bilirubin concentration in amniotic 
ﬂuid and fetal blood in rhesus D alloimmunized anemic fetuses in order 
to speculate on the possible pathway of bilirubin from fetal blood to 
amniotic ﬂuid.
Part 2: Ultrasonographic approach   
We have been performing intrauterine transfusions with a large volume 
load since many years. We investigated (chapter 5) the effects of acute large 
increases of hematocrit on fetal blood ﬂow velocities. This therapeutic 
experiment may help to explain the relationship between hematocrit and 
blood ﬂow velocities in the fetus.
Theoretically, fetal anemia may lead to a reactive increase in cardiac 
contractility and, consequently, to an increased cardiac wall thickness 
and an increased cardiac size. In everyday practice, sonographers often 
mention their impression that the heart is increased in size in a fetus 
with anemia. Therefore, to test this hypothesis and to explore potential 
applications, we assessed (chapter 6) the diagnostic value of cardiac size 
measurements in the prediction of severe alloimmune anemia.
 
Another impression of sonographers during intra-uterine transfusions 
is that the contractility of the fetal heart is decreased after intrauterine 
transfusion. Therefore, we assessed the effect of fetal anemia and 
intrauterine transfusion on ventricular shortening fraction (chapter 7). 
It is hoped that the studies in this thesis will add to a better understanding 
of the physiologic changes and to a more accurate diagnosis and hence to 
the timely therapeutic intervention in fetal anemia.
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Introduction 
The severity of fetal alloimmune anemia can be diagnosed biochemically 
or sonographically. The biochemical method is based on the fact that 
hemolysis results in increased bilirubin concentrations in fetal blood and in 
amniotic ﬂuid.1 Already in 1956, Bevis found that bilirubin concentrations 
in amniotic ﬂuid are indicative of the severity of the hemolytic process in 
fetuses of alloimmunized mothers.2 In 1961, Liley proposed amniotic ﬂuid 
sampling to measure deviation of optical density at 450 nm (Δ OD 450) 
to predict life-threatening fetal anemia in the third trimester.3 
The American College of Obstetricians and Gynecologists (ACOG) still 
recommends serial amniocentesis in pregnancies at risk, followed by 
intrauterine transfusion (IUT) or early delivery when Δ OD 450 values are 
in Liley zone 3 or in the upper third of Liley zone 2 and rising.4 Amniotic 
ﬂuid Δ OD 450 can also be plotted in other charts (Queenan, extended 
Liley) or be used as Ovenstone factor, or transmutance ratio.5-8
The invasive nature of amniocentesis remains a disadvantage, however. 
With each procedure, there is a risk of iatrogenic rupture of the fetal 
membranes or infection, both of which can lead to fetal loss. There is also 
the risk of increasing severity of sensitization by either boosting of antibody 
titer or formation of additional antibodies.9 Since the introduction of 
non-invasive methods to diagnose fetal anemia, the evaluation of the 
diagnostic performance of invasive Δ OD 450 measurement is now 
warranted.10;11
Sonographic prediction of severe anemia is easy when the fetus is 
hydropic. However, treatment results are deﬁnitely worse in hydropic 
than in non-hydropic fetuses.12 Therefore, severe fetal anemia should 
preferably be diagnosed and treated before hydrops develops. During 
the last decade, different methods for this purpose have been proposed: 
sonographic liver13;14 and spleen15 measurements, Doppler measurements 
of the middle cerebral artery10, intrahepatic umbilical vein16;17, descending 
aorta18, splenic artery19 or combined measurements.11;20 Of these methods, 
measurement of Middle cerebral artery (MCA) peak systolic velocity is 
the most widely used. An increased peak systolic velocity in the MCA as 
CHAPTER 2 |  Diagnostic accuracy of Δ OD 450 and MCA
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predictor of severe fetal anemia was ﬁrst described by Mari et al.21 It is 
thought that this increase in systolic velocity is caused by a hyperdynamic 
circulation with increased contractility of the heart and decreased viscosity 
of the blood.18 In a prospective series, Mari et al., established the normal 
median for MCA peak systolic velocity throughout gestation and drew the 
demarcation line between moderate and severe anemia around 1.5 MoM.10
We aimed to compare the accuracy of amniotic ﬂuid Δ OD 450 with the 
accuracy of the more recent non-invasive Doppler measurement of MCA 
peak systolic velocity. Therefore we performed a literature review on the 
accuracy of, ﬁrst, Δ OD 450 and, second, MCA peak systolic velocity. We 
calculated the sensitivities and speciﬁcities for the different cut-offs used in 
each study.
Methods
Δ OD 450 
English language journals indexed in Medline between 1961 and 2003 
were searched for articles addressing amniotic ﬂuid bilirubin levels in the 
management of red cell alloimmunization. Search terms included “rhesus”, 
“Liley”, “Queenan”, “OD 450”, “amniotic bilirubin”, and “amniotic 
optical density”. Selected abstracts were reviewed for relevant information 
on the test characteristics of amniotic ﬂuid Δ OD 450 to predict fetal 
anemia. The references of retrieved articles were reviewed for additional 
articles not identiﬁed through the database search. Data on hydropic 
fetuses were excluded. Two groups were recognized. The ﬁrst group 
describes test characteristics of amniotic ﬂuid Δ OD 450 in the prediction 
of fetal anemia at fetal blood sampling. The second group describes 
test characteristics of amniotic ﬂuid Δ OD 450 in the prediction of fetal 
anemia at birth. Sensitivity, speciﬁcity, and overall accuracy (combined 
rate of true-positive and true-negative results) were calculated for different 
Δ OD 450 cut-offs in the prediction of anemia by two of the authors (ES 
and FV).
21
MCA peak systolic velocity 
We also searched English language journals indexed in Medline between 
1995 and 2005 addressing MCA peak systolic velocity in predicting fetal 
anemia. The following search term was used: “middle cerebral artery and 
fetal anemia”. Selected abstracts were reviewed for relevant information 
on the test characteristics of MCA peak systolic velocity to predict fetal 
anemia. The references of retrieved articles were reviewed for additional 
articles not identiﬁed through the database search. Sensitivity and 
speciﬁcity were calculated for different MCA cut-offs in the prediction of 
anemia by two of the authors (ES and FV). 
Simultaneous Δ OD 450 and MCA peak velocity 
In addition, the search consisted of English language journals indexed in 
Medline between 1995 and 2005 addressing both Δ OD 450 and MCA 
peak systolic velocity in predicting fetal anemia. The following search term 
was used: “amniocentesis and middle cerebral artery”. Selected abstracts 
were reviewed for relevant information on the test characteristics of 
both Δ OD 450 and MCA peak systolic velocity to predict fetal anemia 
in the same patient population. The references of retrieved articles were 
reviewed for additional articles not identiﬁed through the database search. 
Sensitivity, speciﬁcity, and overall accuracy (combined rate of true-positive 
and true-negative results) were calculated by two of the authors (ES and 
FV). 
Results
Studies with test characteristics of Δ OD 450 
The literature search resulted in 73 abstracts. In 28 papers, test 
characteristics were mentioned and these papers were read in detail. 
Twelve additional papers were found by checking the references of 
these papers. Finally, ﬁve papers compared Δ OD 450 with hemoglobin 
concentration obtained by fetal blood sampling and gave sufﬁcient data to 
calculate test characteristics.22-26 All patients in these studies were rhesus-D 
immunized. These papers are listed in Table I. Sensitivities of Liley’s zone III 
and Queenan’s zone 4 in the prediction of severe anemia (not uniformaly 
CHAPTER 2 |  Diagnostic accuracy of Δ OD 450 and MCA
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deﬁned) ranged from 33% to 100%. Sensitivities of the upper half of Liley’s 
zone II (IIB) or Queenan’s zone 3 ranged from 80% to 100%. Table 2 lists 
another 12 studies, where Δ OD 450 was compared with the severity of 
clinically deﬁned fetal anemia or hemoglobin concentration at birth.3;5-
8;27-33 Although the majority of patients in these studies were rhesus-D 
immunized, other antibodies (including anti-Kell) may have played a 
role in some of the patients. In case of anti-Kell antibodies, anemia may 
be partially caused by erythroid precursor damage and not merely by 
hemolysis. Consequently, the haemolytic-induced rise in amniotic ﬂuid 
bilirubin may be less pronounced in case of anti-Kell antibodies and severe 
anemia may remain undetected.34-36
Studies with test characteristics of MCA peak systolic velocity 
This literature search resulted in 75 abstracts. In 32 papers, test 
characteristics were mentioned and these papers were read in detail. 
There were no additional papers found by checking the references of 
these papers. Finally, 14 papers compared MCA peak systolic velocity 
with fetal hemoglobin concentration at fetal blood sampling or at birth 
and gave sufﬁcient data to calculate test characteristics.10;20;37-48 These 
papers are listed in Table 3. Sensitivities of MCA peak systolic velocity in 
the prediction of severe anemia (according to different deﬁnitions) ranged 
from 31% to 100%. 
Studies with test characteristics of both Δ OD 450 and MCA peak systolic 
velocity in the same fetuses 
Our search resulted in 12 abstracts. In 3 papers, test characteristics were 
mentioned and these papers were read in detail. One additional paper 
was found by checking the references of these papers. Finally, three papers 
compared Δ OD 450 and MCA peak systolic velocity with hemoglobin 
concentration and gave sufﬁcient data to calculate test characteristics.49-
51 These papers are listed in Table 4. Sensitivities of Δ OD 450 in the 
prediction of severe anemia (according to different deﬁnitions) ranged 
from 53% to 86%. Sensitivities of MCA peak systolic velocity in the 
prediction of severe anemia (according to different deﬁnitions) ranged 
from 64% to 100%. 
CHAPTER 2 |  Diagnostic accuracy of Δ OD 450 and MCA
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Discussion
This study shows that sensitivities to predict severe anemia at fetal blood 
sampling (Table1) were between 80 % and 100% for Δ OD 450 in the 
upper half of Liley’s zone II (IIB) or Queenan’s zone 3. These results are 
excellent, because the procedure-related risk of amniocentesis is low 
compared to the procedure-related risk of fetal blood sampling. The 
sensitivities of Δ OD 450 in the prediction of neonatal anemia at birth 
(Table 2) were much more variable. This is readily explained by the 
commonly longer time period between amniocentesis and birth. Also, it 
should be noted that different inclusion criteria and different deﬁnitions of 
severe anemia were used in the different studies. 
The ACOG recommends diagnostic amniocentesis for red cell 
alloimmunization with high antibody titers from as early as 20 weeks 
gestation and therapeutic intervention when Δ OD 450 is in Liley’s 
zone 3 or rising in the upper third of zone 2.4 The results of our previous 
study support this guideline: a 95 % sensitivity for severe fetal anemia 
was found.26 However, a speciﬁcity of 50% and the risk associated with 
repeated amniocentesis remain the major drawbacks of this approach. 
In addition, fetal and perinatal procedure-related loss rates are reported 
to be 0.25 to 1% per amniocentesis.52;53 Further, false positive results of 
amniocentesis can lead to unnecessary IUTs with procedure-related fetal 
loss rates of 1 to 3%.54 Finally, another drawback of amniocentesis or fetal 
blood sampling is the risk of feto-maternal hemorrhage that may increase 
the severity of alloimmunization. Feto-maternal hemorrhage occurs in 
2.3% of cases after amniocentesis.9 A signiﬁcant increase in antibody titers 
and induction of additional antibodies occurs in respectively 50% and 26% 
of cases after IUT.9;55;56 Thus, there is still a need for non-invasive tests that 
can predict fetal anemia with equal or higher accuracy. 
Recent studies suggest that arterial and venous Doppler ﬂow velocities in 
fetal vessels accurately predict anemia.10;46;57;58 These studies report that 
Doppler measurements, when performed by experienced operators, have 
sensitivities between 67% and 100% and speciﬁcities between 70% and 
100% in the prediction of severe fetal anemia.10;46;57;58 However, there is a 
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tendency to be overly optimistic about early results with new techniques. 
In the present study, we also performed a literature review on the accuracy 
of Doppler measurements of MCA peak systolic velocity in the prediction 
of severe fetal anemia. The selected studies showed sensitivities and 
speciﬁcities that were comparable to those reported in the Δ OD 450 
studies.
In three small studies, each with less than 40 patients, Doppler and 
Δ OD 450 were compared.46-48 Two of these studies were retrospective, 
only one was prospective. In these studies, the accuracy of MCA peak 
systolic velocity was better than that of Δ OD 450.
From our literature review, we conclude that Δ OD 450 measurement 
predicts severe anemia with sensitivities ranging between 80 and 100 % in 
most studies. In recently published series on MCA Doppler velocimetry, 
sensitivities for the prediction of severe fetal anemia range between 
54 and 100 %. It is still unknown which test, the traditional minimally 
invasive amniocentesis with Δ OD 450 measurements, or the more recent 
non-invasive MCA Doppler measurements, is the more accurate. Only a 
prospective trial, comparing the characteristics of the two tests (Δ OD 
450 and MCA peak systolic velocity) simultaneously measured in the same 
patients, with the gold standard test (fetal hemoglobin concentration) 
can provide the answer. We have been engaged in such a trial, called the 
DIAMOND (“diagnostic amniocentesis or non-invasive Doppler”) study 
and the results of this trial will become available soon.59
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Abstract
Objective: To assess the diagnostic accuracy of the extrapolated Liley curve.
Methods: We searched our database for singleton D-alloimmunized 
pregnancies with non-hydropic fetuses, where amniocentesis was 
performed within 4 days of ﬁrst fetal blood sampling. Amniotic ﬂuid 
Δ OD 450 values were plotted on an extrapolated Liley chart. Sensitivity 
and speciﬁcity were calculated for two commonly used cut-off levels, 
Liley’s zone 3 and the upper third of Liley’s zone 2. Severe fetal anemia was 
deﬁned as a hemoglobin concentration of 5 standard deviations below the 
normal mean for corresponding gestational age.
Results: Seventy-nine pregnancies met our inclusion criteria. Overall 
accuracy of the extrapolated Liley curve in predicting severe fetal anemia 
was 75% (95%CI: 64-84) for zone 3 and 86% (95%CI: 77-93) when the 
upper third of zone 2 was included. Sensitivity of Δ OD 450 values in Liley’s 
zone 3 or the upper third of Liley’s zone 2 was 95% (95%CI: 74-100) before 
and 98% (95%CI: 89-100) after 27 weeks.
Conclusion: Liley’s extrapolated curve predicts severe fetal anemia with 
reasonable accuracy and high sensitivity. 
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Introduction
In 1961, Liley proposed amniotic ﬂuid sampling to measure deviation of 
optical density at 450 nm (Δ OD 450) to predict life-threatening fetal 
anemia in the third trimester.1 After intrauterine intravascular transfusion 
(IUT) became a relatively safe procedure as early as 18 weeks, the original 
Liley chart was extrapolated to the second trimester to also predict severe 
anemia there. This was done by linear extension of the two lines that 
divide Liley’s three zones.2-4 The American College of Obstetrians and 
Gynecologists (ACOG) recommends serial amniocentesis in pregnancies 
at risk, followed by IUT or early delivery when Δ OD 450 values are in Liley 
zone 3 or in the upper third of Liley zone 2 and rising.5 Several authors 
have proposed management schemes based on different cut-off values for 
Δ OD 450.6-12 Among these, the Queenan chart is the most popular.10  In 
1986, Nicolaides et al. concluded that Δ OD 450 values were unreliable as 
predictors of severe anemia in second trimester pregnancies.13 Others also 
questioned the value of Δ OD 450 during the third trimester.8,1 4-16 These 
doubts applied both to Liley’s original chart and to modiﬁed versions.14 
However, these studies included amniotic ﬂuid samples that were taken 
more than a week before the ‘gold standard’ blood sample, and included 
cases with Kell antibodies where anemia is partially due to erythroid 
precursor damage and not merely the results of hemolysis.17, 18 These 
studies also included cases of hydrops fetalis, where Δ OD 450 is not only 
unreliable but also superﬂuous.19,20
A critical evaluation of the diagnostic performance of Δ OD 450 
measurement is warranted because new non-invasive methods are being 
introduced to replace amniocentesis.21,22 These methods are based on the 
fact that blood viscosity, which declines along with hematocrit, is inversely 
related to maximum blood ﬂow velocities in fetal vessels. The proponents 
of these Doppler methods claim great accuracy in the prediction of fetal 
anemia.22-25 As a ﬁrst step in comparing amniocentesis and non-invasive 
Doppler, we evaluated the ability of Δ OD 450 values to predict severe 
fetal anemia.
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Methods
Leiden University Medical Center is the national referral center for the 
treatment of alloimmune fetal anemia in The Netherlands. Our methods 
for diagnosing and treating severe fetal anemia have been described 
previously.26 Brieﬂy, patients with high antibody titers are followed with 
weekly ultrasound examinations for signs of incipient hydrops or fetal 
anemia. These signs include hepatosplenomegaly, cardiomegaly, placental 
thickening, decreased fetal movements, and increased maximum ﬂow 
velocities in the descending aorta and intrahepatic umbilical vein.21 
When severe anemia is suspected at or after 27 weeks, amniocentesis for 
Δ OD 450 is performed to avoid unnecessary fetal blood sampling. For 
the data in this study, we followed our center’s established procedure, 
performing the ﬁrst IUT when Δ OD 450 was in zone 3, or in upper third 
of zone 2 and rising.5 In some fetuses after 27 weeks and in most  before 
27 weeks, the decision to perform the ﬁrst IUT was based on ultrasound 
ﬁndings alone. In these cases, when a transamniotic approach to the fetal 
umbilical vein was necessary, amniotic ﬂuid was collected and Δ OD 450 
measured for the purpose of this study. This procedure was approved 
of by the hospital’s ethical committee, and in each case oral informed 
consent of the mother was obtained. The data of all patients were stored 
in our database (Paradox 9.0, Corel Corporation, Ottawa, Canada). 
We searched this database for the period January 1988 to October 
2000 for contemporaneous amniotic ﬂuid and fetal blood samples 
that met the following criteria: they were taken from fetuses that were 
1) Rhesus D-alloimunized, 2) non-hydropic, 3) not previously transfused, 
4) singleton; and 5) amniotic ﬂuid samples were taken less than four days 
before fetal blood sampling.
Amniotic ﬂuid samples (5-10 ml), protected from light during transport, 
were centrifuged at 1000g for 10 minutes to remove vernix and 
erythrocytes. The absorption of the supernatant was measured at the 
wavelengths 365, 450 and 550 nm with an UltrospecPlus spectrofotometer 
(Amersham Pharmacia Biotech, Little Chalfont, UK). The bilirubin 
absorption, expressed as Δ OD 450, was calculated as the difference 
between the measured absorption at 450 nm and the background 
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absorption at 450 nm. The latter was derived, as described by Liley, from 
the logarithmic function of the absorptions between 365 and 550 nm.1 
Each Δ OD 450 was measured and entered into our database within an 
hour after amniocentesis. Only values at or after 27 weeks were used 
clinically. At IUT, a small portion of the initial fetal blood sample was 
used for on the spot measurement of hemoglobin concentration and 
mean red cell volume. Fetal hematocrit was used to calculate the volume 
of intravascular red cell transfusion.27 The remaining fetal blood of the 
initial sample was sent to our central laboratory for hematological and 
other measurements. These latter values were automatically entered into 
our database and checked by a specialized nurse. Statistical analysis was 
performed using SPSS 10.0 (SPSS Inc., Chicago, USA).
 
We copied Liley’s original chart,1 and found that the upper line that 
deﬁned zone 2 crossed the vertical lines corresponding with 27 and 41 
weeks at Δ OD 450 of 0.260 and 0.077 respectively; the (parallel) lower 
line deﬁning zone 2 crossed the vertical line corresponding with 27 weeks 
at 0.066. We then drew a third parallel line through the Δ OD 450 of 0.160 
at 27 weeks, as the delineation of the upper third of zone 2 (2c). All three 
lines were extrapolated backwards in a linear fashion from 27 to 18 weeks. 
Standardized amniotic ﬂuid Δ OD 450 was calculated by dividing the 
Δ OD 450 measurement  by the value on the line between zones 1 and 
2 for the corresponding gestational age. For example, a Δ OD 450 of 
0.260 nm at 27 weeks and a Δ OD 450 of 0.141 at 34 weeks are both on 
the border between zone 2 and 3. Both correspond with a standardized 
Δ OD 450 of 3.94. The latter value is found by dividing the Δ OD 450 
measurements (0.260 and 0.141) by the cut-off values on the line between 
zone 1 and zone 2 (0.066 and 0.036 respectively) for the corresponding 
gestational ages. In this way, the standardized Δ OD 450 is independent 
of gestational age and indicates how much the measured value was 
higher than the corresponding boundary value between zone 1 and 2. 
Standardized values above 3.94 correspond to Liley values in zone 3.
Normal fetal hemoglobin values increase during gestation. We used the 
reference values proposed by Nicolaides et al. in 1988.28 These reference 
values were obtained from 210 fetuses, ranging from 17 to 40 weeks, and 
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they have a constant standard deviation (SD) of 1 g/dl.28 For the purpose 
of this study, we deﬁned severe anemia as hemoglobin concentrations 
> 5 SD below the normal mean for gestational age. This cut-off was 
chosen because a higher cut-off would include fetuses in whom the need 
of treatment is not warranted, whereas a lower cut-off would include 
too many cases of hydrops fetalis, which would not only render the 
use of diagnostic amniocentesis redundant, but would also worsen the 
prognosis signiﬁcantly.29 Moderate anemia was deﬁned as a hemoglobin 
concentration > 2 SD but ≤ 5 SD below the normal mean for gestational 
age. Standardized fetal hemoglobin scores were deﬁned as the number of 
SDs that the actual value deviated from the normal mean for gestational 
age.
Sensitivity, speciﬁcity, and overall accuracy (combined rate of true-positive 
and true-negative results) were calculated for different Δ OD 450 cut-offs 
(Liley 3 and 2c) in the prediction of severe  anemia, together with their 
exact 95% CI. Separate analyses were done for gestational ages above 
and below 27 completed weeks. Pearson R2  were calculated between 
standardized Δ OD 450 and standardized hemoglobin. To study if this 
relation differed before and after 27 weeks, linear regression was performed 
with standardized hemoglobin as outcome variable and standardized 
Δ OD 450 as independent variable. The slopes of the regression lines 
before and after 27 weeks were compared by adding a dummy variable in 
the regression model, indicating whether the pregnancy was more than 
27 weeks, and testing the signiﬁcance of the interaction term between 
standardized Δ OD 450 and the dummy variable.
Results
In the 13 year study period, 249 fetuses were treated for alloimmune 
anemia with one or more IUT’s; 139 of these were anti D-alloimmunized 
and non-hydropic, and 79 of them fulﬁlled our inclusion criteria of 
singletons with contemporaneous sampling of amniotic ﬂuid and fetal 
blood at their ﬁrst IUT. Mean gestational age of these 79 fetuses at 
the time of ﬁrst IUT was 29 completed weeks (range 20-35) and mean 
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hemoglobin concentration was 6.3 g/dl (range 3.1- 13.2). Mean age of the 
79 women was 32 years (range 23-44), and parity was 3.3 (range 2-14). 
There was one fetal and one neonatal death among these 79 cases. The 
fetal death occurred at 25 weeks due to an intrauterine infection following 
the 3rd IUT. In this case, the ﬁrst IUT (the data from which were used in 
this study) took place at 21 weeks. The neonatal death occurred after an 
emergency cesarean section, 4 hours after the ﬁrst IUT. This IUT took place 
at 35 weeks and was complicated by continuing leakage of blood from the 
cord at the puncture site.
Figure 1 plots hemoglobin values of these 79 fetuses against their 
gestational age, compared to the normal range (mean ± 2 SD) of fetal 
hemoglobin concentration as established by Nicolaides et al.,28 as well 
as the –5 SD line that we used as the cut-off for severe anemia. Of the 79 
fetuses included in this study, only one had a hemoglobin concentration in 
the normal range, 11 showed moderate anemia, and 67 had severe anemia 
at the time of ﬁrst fetal blood sampling. Amniotic ﬂuid Δ OD 450 values of 
the 79 fetuses are shown on the extrapolated Liley chart (Figure 2).
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Figure 1 - Hemoglobin values of 79 non-hydropic Rhesus D-alloimmunized fetuses at ﬁrst 
blood sampling, plotted against their gestational age. The grey zone between 3 upper ascending 
lines marks the limit of normal (mean ± 2 SD) fetal hemoglobin concentrations. The lower line 
seperates moderate (between –2 and –5 SD) from severe (< –5 SD) fetal anemia.
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Figure 3 shows the relationship between standardized hemoglobin values 
at ﬁrst IUT and contemporaneous standardized Δ OD 450 values of 
the 79 fetuses in our study. The linear correlation between standardized 
Δ OD 450 on a logarithmic scale and standardized hemoglobin was low 
(R2 = 0.096). Pearson R2 between Δ OD 450 and hemoglobin values was 
0.315 for the samples taken before 27 weeks (n=24) and 0.018 when taken 
at or after 27 weeks (n=55). However, the slopes of the regression lines, 
with standardized hemoglobin as outcome variable and standardized 
Δ OD 450 as independent variable, did not differ signiﬁcantly (p=0.21)  
before and after 27 weeks pregnancy. In addition, in Figure 3, horizontal 
lines were drawn at the thresholds of Liley zones 1, 2c and 3 and a vertical 
line at the threshold of severe anemia. As such, Figure 3 can be read as a 
two-by-two table. Cases on the left of the vertical line were severely anemic, 
Figure 2 - Amniotic ﬂuid Δ OD 450 values of 79 non-hydropic Rhesus D-alloimmunized fetuses 
at the time of ﬁrst blood sampling, plotted in the extrapolated Liley curve. No anemia () 
corresponds with hemoglobin concentrations within the normal range (mean ± 2 SD) for 
gestational age; moderate anemia () corresponds with hemoglobin concentrations between 
2 and 5 SD below the normal mean; and severe anemia () corresponds with fetal hemoglobin 
concentrations > 5 SD below the normal mean. The vertical axis (Δ OD 450) has a logarithmic 
scale and the horizontal axis (gestational age) has a linear scale. The vertical broken line is drawn 
at 27 weeks to divide Liley’s original chart from the extrapolated part. The descending broken 
line divides zone 2 in an upper third (2c) and two lower thirds. Note that this upper third is on a 
visual and not on a logaritmic scale. 
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and those above the chosen horizontal cut-off line (e.g., zone 3 or zone 
2c) were true positives and those below were false negatives. Cases on the 
right of the vertical line were non-anemic or only moderately anemic and 
those above the chosen cut-off were false positives, while those below were 
true negatives. Table 1 lists the two-by-two tables and test characteristics 
of amniotic ﬂuid Δ OD 450 in the prediction of severe anemia. Accuracy 
of the extrapolated Liley curve in predicting severe fetal anemia was 75% 
(95%CI: 64-84) for zone 2 and 86% (95%CI: 77-93) when the upper third 
of zone 2 was included. Sensitivity of Liley’s zone 3 was 74% (95%CI: 49-91) 
before and 81% (95%CI: 67-91) after 27 weeks. Sensitivity of Liley’s zone 3 
including zone 2c was 95% (95%CI: 74-100) before and 98% (95%CI: 89-
100) after 27 weeks. 
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Figure 3 - Relationship between standardized Δ OD 450 and standardized hemoglobin 
concentrations in 79 non-hydropic Rhesus D-alloimmunized fetuses at the time of ﬁrst blood 
sampling. Amniotic ﬂuid Δ OD 450 were standardized by dividing the actual value by the value 
on the line between zone 1 and 2 for corresponding gestational age. Standardized hemoglobin 
concentrations were deﬁned as the number of standard deviations that the actual value deviated 
from the normal mean for gestational age. The vertical broken line is drawn at the threshold of 
severe anemia (–5 SD). Thus, this ﬁgure can be read as a two-by-two table: cases on the left of 
the vertical line were severely anemic, and those above the chosen horizontal cut-off line (e.g., 
zone 3 or zone 2c) were true positives and those below were false negatives. Cases on the right of 
the vertical line were non-anemic or only moderately anemic, and those above the chosen cut-off 
were false positives, while those below were true negatives.  
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Discussion
We compared Δ OD 450 with contemporaneous hemoglobin 
concentration in non-hydropic fetuses who were given their ﬁrst IUT. The 
correlation between Δ OD 450 and fetal hemoglobin concentration in 
our study was weak. However, the clinical usefulness of Δ OD 450 was 
good since Liley’s zone 3 and 2c predicted severe anemia with an overall 
sensitivity of 79% and 97% respectively. These sensitivities were roughly the 
same at gestational ages of 20 to 27 weeks and 27 to 35 weeks. Compared 
to previous studies on this subject,13-15,30 we used very stringent inclusion 
criteria and collected data on a relatively large number of patients. The 
data were prospectively collected in our clinical practice, and we adhered 
to current guidelines.5  We did not measure hemoglobin concentration 
in fetuses after 27 weeks with Δ OD 450 in Liley’s zone 2 unless repeated 
measurements showed a rising trend or ultrasound indicated a high risk of 
fetal anemia.
Table 1 - Two-by-two tables and test characteristics of Δ OD 450 in the prediction of severe anemia
Number Range of 
     of gestational Test HB-deﬁcit Hb-deﬁcit Sensitivity Speciﬁcity Accuracy
patients age (weeks) cut-off > 5 g/dl ≤ 5 g/dl (%) (%) (%)
    79 20 - 35 ≥ Zone 3 53 6 79  50 75
  < Zone 3 14 6
  ≥ Zone 2c 65 9 97  25 86
  < Zone 2c  2 3
    24 < 27 ≥ Zone 3 14 0 74 100 79
  < Zone 3  5 5
  ≥ Zone 2c 18 2 95  60 88
  < Zone 2c  1 3
    55 ≥ 27 ≥ Zone 3 39 6 81  14 73
  < Zone 3  9 1
  ≥ Zone 2c 47 7 98  0 85
  < Zone 2c  1 0
Hb: Hemoglobin concentration; Hb-deﬁcit: Difference between actual Hb and mean Hb for 
corresponding gestational age
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In 1986, Nicolaides et al. published a paper with the challenging title 
“Have Liley charts outlived their usefulness?” in which they suggested that 
second trimester Δ OD 450 values were unreliable in predicting severe 
anemia and that fetal blood sampling should replace amniocentesis.13 
After excluding hydropic fetuses from that study, it appears that the 
upper half of Liley’s zone 2 had a 94% sensitivity and a 43% speciﬁcity 
in predicting fetal hemoglobin concentration < 6 g/dl.13 In 1998, 
Rahman et al. conﬁrmed the results of Nicolaides study and also stated 
that predictions made on the basis of second trimester Δ OD 450 
measurements are inaccurate.30 They found an 80% sensitivity of 
Queenan’s zone 3 to predict a fetal hematocrit below 15%. Nevertheless, 
given the difference in procedure-related risk between amniocentesis 
and fetal blood sampling, we believe that sensitivities between 80% and 
100%, as found by using the upper third of Liley’s zone 2, are acceptable. 
Therefore, we argue that Δ OD 450 measurements in the second and third 
trimester are still useful. 
The ACOG recommends diagnostic amniocentesis for alloimmunization 
with high antibody titers from as early as 20 weeks gestation and 
therapeutic intervention when Δ OD 450 is in Liley’s zone 3 or rising in the 
upper third of zone 2.5 The results of our study support this guideline: a 
95% sensitivity for detecting severe fetal anemia was found. A speciﬁcity 
of  50% or less and the risk of repeated amniocentesis remain the major 
drawbacks of this approach. False positive results of amniocentesis can 
lead to unnecessary IUTs with procedure-related fetal loss rates of 1 to 
3%.31 Fetal and perinatal procedure-related loss rates are reported to be 
0.25 to 1% per amniocentesis.32,33 Another drawback of amniocentesis 
or fetal blood sampling is the risk of feto-maternal hemorrhage which 
can increase the severity of alloimmunization. Feto-maternal hemorrhage 
occurs in 2.3% of cases after amniocentesis, and a signiﬁcant increase 
in antibody titers occurs in 50% of cases after IUT.34,35 Thus, there is still 
a need for non-invasive tests that can predict fetal anemia with equal or 
higher accuracy. 
Recent studies suggest that arterial and venous Doppler ﬂow velocities 
in fetal vessels accurately predict anemia.22-25  These studies report that 
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Doppler measurements have sensitivities between 63% and 100% and 
speciﬁcities between 70% and 100% in the prediction of severe fetal 
anemia when performed by experienced operators.22-25 However, there is a 
tendency to be overly optimistic about early results with new techniques. 
We are presently involved in a prospective multicenter trial to compare the 
diagnostic accuracy between Δ OD 450 measurements and maximum ﬂow 
velocity in the fetal middle cerebral artery and the intrahepatic umbilical 
vein. Until the results of such prospective studies are available, we suggest 
that amniocentesis for Δ OD 450 measurement is still important  in the 
management of severe Rhesus D-alloimmunization.
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Abstract
We studied the relationship between bilirubin concentrations in amniotic 
ﬂuid and fetal blood in 68 non-hydropic rhesus D-alloimmunized anemic 
fetuses at ﬁrst blood sampling. In these alloimmunized fetuses, the 
amniotic ﬂuid / fetal blood ratio for bilirubin decreased from 0.09 at 
28 weeks to 0.05 at 33 weeks. In normal fetuses, amniotic ﬂuid / fetal 
blood ratios for bilirubin, and for albumin, are in the same range and 
show a similar decrease during gestation. We conclude that amniotic 
ﬂuid bilirubin concentration is determined, ﬁrstly,  by fetal blood bilirubin 
concentration and, secondly, by the amniotic ﬂuid / fetal blood ratio 
of albumin. Among ﬁve possible pathways bilirubin could take to build 
up a concentration in amniotic ﬂuid (fetal kidneys, lungs, skin, bowel, 
membranes), the intramembranous pathway is the only one that is 
compatible with the amniotic ﬂuid / fetal blood ratios for bilirubin that we 
found and must therefore be the most important. 
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Introduction
Bilirubin is formed during the degradation of haem-containing 
compounds, mainly hemoglobin (Rosenthal, 1992). Bilirubin 
concentration is about four times higher in fetal than in maternal blood 
(Girling, Dow and Smith, 1997;  Nava et al., 1996) As a result of this 
concentration gradient, the unconjugated (liposoluble) bilirubin diffuses 
through trophoblastic layers from fetal to maternal blood (Odell, 
1959). It is unclear whether active or passive carrier-mediated transport 
mechanisms play an additional role in placental transfer (Serrano et al., 
2002). Glucuronyl transferase activity in the fetal liver is minimal, less than 
1% of its activity in neonatal and later life, and only a minor fraction of 
fetal bilirubin is conjugated (Kawade and Onishi, 1981; Nava et al., 1996). 
In the fetal situation, this low glucuronyl transferase activity is probably 
beneﬁcial because the clearance of conjugated (hydrophilic) bilirubin 
through the placental barrier is very slow (Bashore, Smith and Schenker, 
1969). Unconjugated (hydrophobic) bilirubin in fetal and maternal blood 
is linked to albumin almost completely, and only a minute fraction is free 
(Brodersen, 1980).
Some of the fetal bilirubin is excreted into the amniotic ﬂuid 
compartment, and less than 10% of this amniotic ﬂuid bilirubin is 
conjugated (Halitsky and Krumholz, 1970). Each day, the fetus swallows 
about 75% of the amniotic ﬂuid volume (Brace, 1999). Amniotic ﬂuid 
bilirubin concentration is an important diagnostic tool in the management 
of blood group alloimmunization (Liley, 1961). Little is known, however, 
about how bilirubin reaches the amniotic ﬂuid. Theoretically, there are ﬁve 
major possible pathways bilirubin can take to leave the fetal circulation 
and enter the amniotic ﬂuid: via fetal kidneys, lungs, skin, bowel, or via 
placenta and membranes, which is called the intramembranous pathway. 
A ﬁrst possible pathway would be via the kidneys. Fetal urine is, after 
all, the major constituent of amniotic ﬂuid after 16-weeks´ gestation. 
A second pathway would be via the lungs. Fetal lung ﬂuid contributes 
to approximately 10% of amniotic ﬂuid (Brace, 1999). Many clinicians 
and investigators believe that the fetal lung pathway explains the 
clinically useful relation between amniotic ﬂuid bilirubin concentration 
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and the degree of fetal anemia (American College of Obstetricians and 
Gynecologists, 1996). A third possible pathway, excretion of liposoluble 
substances through the fetal skin along a concentration gradient, probably 
occurs early in pregnancy, but is hampered during the second half of 
human gestation due to increasing keratinisation (Evans and Rutter, 
1986;  Parkin, Lind and Cheyne, 1969;  Parmley and Seeds, 1970). Passage 
of meconium is a fourth possible pathway for bilirubin to enter the 
amniotic ﬂuid. Fetuses regularly pass meconium into the amniotic ﬂuid 
and small lumps of meconium have regularly been seen during fetoscopy 
(Hakguder et al., 2002). A ﬁfth possible pathway is the intramembranous 
pathway (Gilbert and Brace, 1989). The fetal surface of the placenta is 
well vascularized and probably plays an important role in the volume 
regulation and composition of amniotic ﬂuid (Gilbert, Eby-Wilkens, and 
Tarantal, 1997). Under normal conditions, diffusion of ﬂuid and solutes 
between amniotic ﬂuid and fetal blood along this pathway is a fairly rapid 
process, one that has been shown to occur in both directions (Bashore et 
al., 1969; Gilbert and Brace, 1989). 
We wanted to study bilirubin concentrations in human amniotic ﬂuid 
and fetal blood in cases with highly increased hemoglobin degradation, 
in order to gain more insight into the enigmatic relation between these 
concentrations and to possibly draw some conclusions regarding the 
origin of amniotic ﬂuid bilirubin.
Methods
Leiden University Medical Center is the national referral center for the 
treatment of fetal anemia in the Netherlands. Our methods for diagnosis 
and treatment of severe fetal alloimmune anemia have been described 
previously (Kanhai et al., 1990). We searched our database from January 
1988 to October 2000 for contemporaneous amniotic ﬂuid and fetal 
blood samples that were taken from singleton, Rhesus D-alloimmunized, 
non-hydropic, and not previously transfused fetuses. Amniotic ﬂuid 
samples had to have been taken less than four days before fetal blood 
sampling.
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Fetal blood samples were sent to our central laboratory for bilirubin and 
hematological measurements. Values were automatically entered into our 
database and checked by a specialized nurse. Amniotic ﬂuid samples (5-
10 ml), protected from light during transport, were centrifuged at 1000g 
for 10 minutes to remove vernix and erythrocytes. The absorption of the 
supernatant was measured at the wavelengths 365, 450 and 550 nm with 
an UltrospecPlus spectrophotometer (Amersham Pharmacia Biotech, 
UK). The bilirubin absorption, expressed as Δ OD 450, was calculated 
as the difference between the measured absorption at 450 nm and the 
background absorption at 450 nm, derived from the logarithmic function 
of the absorptions between 365 and 550 nm (Liley, 1961). 
Normal total bilirubin concentrations in fetal blood increase during 
gestation. We used the reference values proposed by Nava et al., 1996, 
which were derived from a large number of normal fetuses undergoing 
percutaneous umbilical blood sampling between 18 and 39 weeks (Nava 
et al., 1996). Normal bilirubin concentrations in amniotic ﬂuid decrease 
during gestation. We used the reference values proposed by Nicolaides 
et al., 1986;  these were derived from a large number of amniocenteses 
in normal pregnancies, equally distributed between 16 and 37 weeks 
(Nicolaides et al., 1986). A factor of 1.585 was used to convert all 
Δ OD 450 values to bilirubin concentrations (mg/dl) (Egberts et al., 2002, 
Egberts et al., 2003). Normal concentrations of albumin in amniotic ﬂuid 
and fetal blood were based on the literature (Legras et al., 1978; Takagi et 
al., 1989).
Results
We found 68 contemporaneous amniotic ﬂuid and blood samples from 
untransfused non-hydropic D-alloimmunized fetuses. Mean gestational 
age was 29 weeks (range 21-35). Mean fetal hemoglobin concentration 
was 6.1 g/dl (range 3.1-10.1). Figure 1 shows the individual hemoglobin 
concentrations of fetuses in our study plotted against their gestational 
age. Eight fetuses were moderately anemic (hemoglobin concentration 2 
to 5 standard deviations below the normal mean) and 60 were severely 
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anemic (hemoglobin concentration more than 5 standard deviations 
below the normal mean) at the time of ﬁrst blood sampling. Mean total 
bilirubin concentration in fetal blood was 5.8 mg/dl (range 1.9-11.4). In 
all but three cases, the conjugated bilirubin concentration was less than 
10% of the total bilirubin concentration. Figure 2 plots the concentrations 
of total bilirubin in fetal blood against gestational age. Values were above 
normal in all but one fetus. Figure 3 shows the amniotic ﬂuid bilirubin 
concentrations against gestational age. Values were above normal in all 
but three fetuses. In our study, 50 amniotic ﬂuid bilirubin values were in 
Liley’s zone 3, 13 in the upper third of zone 2 and the remaining 5 in the 
lower two thirds of zone 2 (Liley, 1961; Sikkel et al., 2002). Figure 4 shows 
the ratios between bilirubin concentrations in amniotic ﬂuid and in blood 
of the fetuses in our study, plotted against their gestational age. Roughly, 
these ratios decreased from around 0.09 at 28 weeks to around 0.05 at 33 
weeks. Thus, in our alloimmunized fetuses, these ratios were in the same 
range as bilirubin and albumin ratios in non-immunized fetuses (Nava et 
al., 1996; Nicolaides et al., 1986; Legras et al., 1978; Takagi et al., 1989), 
and showed a similar pattern of decrease as pregnancy progressed. 
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Figure 1 - Hemoglobin values of 68 non-hydropic rhesus D-alloimmunized fetuses at ﬁrst blood 
sampling, plotted against their gestational age. The grey zone between the three upper ascending 
lines marks the limits of normal fetal hemoglobin concentrations (mean ± 2 standard deviations) 
(Nicolaides et al., 1988). The lower line separates moderate (between –2 and –5 standard 
deviations) from severe (less than –5 standard deviations) fetal anemia.
53
0
2
4
6
8
10
12
18 20 22 24 26 28 30 32 34 36
Gestational age (weeks)
Bi
lir
ub
in 
co
nc
en
tra
tio
n i
n f
eta
l b
loo
d (
mg
/dl
)
+ 2 SD
- 2 SD
Normal
Figure 2 - Total bilirubin values in blood of 68 non-hydropic rhesus D-alloimmunized fetuses at 
ﬁrst blood sampling, plotted against their gestational age. The grey zone between the three lines 
marks the limits of normal (mean ± 2 standard deviations) total bilirubin concentration in fetal 
blood (Nava et al., 1996).
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Figure 3 - Amniotic ﬂuid bilirubin values of 68 non-hydropic rhesus D-alloimmunized fetuses at 
ﬁrst blood sampling, plotted against their gestational age. The grey zone between the three lines 
marks the limits of normal (mean ± 2 standard deviations) bilirubin in amniotic ﬂuid (Nicolaides 
et al., 1986). 
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Discussion
We studied bilirubin concentrations in amniotic ﬂuid and blood in 68 
alloimmunized fetuses and found that bilirubin values in blood were on 
average three times as high as in non-anemic fetuses. All values were, 
however, well below the threshold associated with a kernicterus risk 
(Poland, 2002). Amniotic ﬂuid bilirubin values were also elevated, and 
most values were in Liley’s zone 3, which warrants immediate treatment. 
We then calculated ratios of bilirubin in amniotic ﬂuid to that in blood for 
these anemic fetuses and found these ratios to be very similar to ratios in 
normal fetuses. These ratios were also very similar to ratios of albumin in 
amniotic ﬂuid to that in blood in normal fetuses. These ratios decreased 
with gestational age from around 0.09 at 28 weeks to 0.05 at 33 weeks. 
The strength of the present study is that we measured bilirubin in a 
relatively large number of D-alloimmunized anemic fetuses. None of 
these fetuses were hydropic and this may be important because hydrops 
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Figure 4 - Ratio between amniotic ﬂuid and fetal blood concentrations of total bilirubin in 68 
non-hydropic rhesus D-alloimmunized fetuses at ﬁrst blood sampling, plotted against their 
gestational age. The black line marks the ratio between normal bilirubin concentrations in 
amniotic ﬂuid and fetal blood (Nava et al., 1996; Nicolaides et al., 1986). The grey open triangles 
mark the ratio between normal albumin concentrations in amniotic ﬂuid and fetal blood (Legras 
et al., 1978; Takagi et al., 1989).
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is associated with an increase in the amniotic ﬂuid / fetal blood ratio 
of albumin: it has been shown that in hydropic fetuses, the blood 
concentration of albumin decreases and the amniotic ﬂuid concentration 
of albumin increases (Nicolaides, Warenski and Rodeck, 1985; Cherry, 
Rosenﬁeld and Kochwa, 1970). A weakness of our study is that amniotic 
ﬂuid samples were taken up to three days before fetal blood sampling 
(we called this contemporaneous) whereas one would prefer completely 
simultaneous samples. Prehydropic changes in some of our severely anemic 
fetuses may also have inﬂuenced our results. Finally, we did not measure 
bilirubin in non-anemic fetuses, and therefore we had to use normal mean 
values of bilirubin in amniotic ﬂuid and in blood found in the literature 
(Nava et al., 1996; Nicolaides et al., 1986). Still, we think our results 
suggest rather convincingly that amniotic ﬂuid / fetal blood bilirubin ratios 
in anemic and non-anemic fetuses are very similar. 
Albumin contains one high afﬁnity binding site for bilirubin and one or 
two secondary sites of lower afﬁnity (Rosenthal, 1992). Unconjugated 
bilirubin is hydrophobic and in aqueous solutions linked to albumin 
almost completely (Rosenthal, 1992). Transfer of bilirubin between body 
compartments, however, is due to diffusion of albumin-free unconjugated 
bilirubin (Odell, 1959). The bilirubin gradient between compartments 
is a function of the concentration of albumin-free bilirubin and thus of 
the ratio between bilirubin and albumin in both compartments (Odell, 
1959). As early as 1970, Cherry et al. proposed a strong experimental 
argument for this theory, measuring Δ OD 450 before and 12 hours 
after the injection of albumin in the amniotic ﬂuid compartment in 3 
alloimmunized pregnancies (Cherry, Rosenﬁeld and Kochwa, 1970). 
They found a highly signiﬁcant linear relationship between Δ OD 450 
and albumin concentration. In 1967, Cherry and Rosenﬁeld had already 
suggested that bilirubin / protein ratios in amniotic ﬂuid could replace 
plotting Δ OD 450 in Liley’s curve and suggested a bilirubin / protein 
ratio of 0.55 as the cut-off. In 1974, Bosch et al. found that this “Cherry-
ratio” led to slightly more accurate predictions than the Liley chart 
(Bosch, Robinson and Fisher, 1974). Our study suggests the existence of 
a ﬁxed amniotic ﬂuid / fetal blood ratio for bilirubin. This ratio decreases 
between 26 and 34 weeks, probably concurrent with the decrease of the 
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amniotic ﬂuid / fetal blood ratio for albumin. It is still unclear which 
factors contribute to the albumin concentration in amniotic ﬂuid. In 
animal experiments, it has been shown that amniotic ﬂuid albumin is, to 
a large extent, of maternal origin and that clearance occurs through fetal 
swallowing and digestion, as well as through absorption through fetal 
membranes (Gitlin et al., 1972; Faber and Anderson, 2002). It seems clear 
that the origins and pathways of amniotic ﬂuid albumin are distinct from 
those of bilirubin, but they are, at present, even more puzzling. 
We conclude that the bilirubin concentration in amniotic ﬂuid reﬂects 
the bilirubin concentration in fetal blood. This ﬁnding provides a logical 
explanation for the longstanding good performance of Liley’s method in 
the diagnosis of severe fetal alloimmune hemolytic anemia. Further, we 
found that the amniotic ﬂuid / fetal blood ratio for bilirubin mimicked 
that of albumin. Therefore, we suggest that the ratio between bilirubin 
and albumin in amniotic ﬂuid equals the ratio between bilirubin and 
albumin in blood. The existence of a ﬁxed ratio would shed some light on 
the origin of human amniotic ﬂuid bilirubin: of the ﬁve possible pathways 
bilirubin could take, only one would agree with such a ﬁxed ratio. To 
our knowledge, urinary or alveolar ﬂuid concentrations of bilirubin have 
not been measured in the human fetus. It is very improbable, however, 
that urine or alveolar ﬂuid contribute substantially to the bilirubin 
concentration in amniotic ﬂuid because the protein concentrations in 
both fetal urine and alveolar ﬂuid are 100 to 200 times lower than in fetal 
plasma (Awad et al., 2002; Boston et al., 1968; Muller et al., 1996; Gitlin 
et al., 1972). The protein concentration in amniotic ﬂuid, on the other 
hand, is only 10 to 20 times lower than in fetal plasma (Legras et al., 1978; 
Takagi et al., 1989; Faber and Anderson, 2002; Nicolaides, Warenski and 
Rodeck, 1985). Because of the very low albumin concentrations in urine 
and alveolar ﬂuid, these ﬂuids act as a barrier for unconjugated bilirubin 
leaving the plasma and entering the amniotic ﬂuid compartment. A 
meconial origin of amniotic ﬂuid bilirubin is inconsistent with a clinically 
relevant correlation between amniotic ﬂuid and fetal blood bilirubin 
concentration. The fetal skin probably serves as a major pathway for 
solute and water exchange between amniotic ﬂuid and fetus in early 
gestation. Fetal skin keratinisation begins at approximately 17 weeks 
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and a complete stratum corneum is present by approximately 25 weeks 
(Hashimoto et al., 1966). At 14 to 18 weeks, the skin has been shown to 
have similar permeability as chorion laeve and amnion. However, in fetuses 
of 24 weeks and older, the skin has become quite impermeable (Parmley 
and Seeds, 1970). The fetal membranes, on the other hand, retain a high 
permeability until term (Lloyd et al., 1969). Therefore, bilirubin exchange 
between fetal blood and amniotic ﬂuid most probably occurs through the 
intramembranous pathway, where both excretion and reabsorption of 
bilirubin take place throughout gestation. 
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Abstract
ObjectIve: To measure the effects of acute large increases of the hematocrit 
on fetal peak arterial and maximum venous blood ﬂow velocities. 
Methods: Middle cerebral artery peak ﬂow velocities and umbilical vein 
maximum ﬂow velocities were measured before, immediately after, and 12-
24 h after intrauterine transfusions. All measurements were standardized 
for gestational age. 
Results: Complete measurements were obtained at 60 intrauterine 
transfusions. The mean hematocrit before intrauterine transfusion was 
0.19 l/l and after 0.40 l/l. The middle cerebral artery peak ﬂow velocity 
decreased immediately after transfusion in 59 of the 60 cases. There was a 
rise in umbilical vein maximum ﬂow velocity immediately after intrauterine 
transfusion in 37 of the 60 cases. The sensitivity of middle cerebral artery 
peak ﬂow velocity for severe anemia before intrauterine transfusion was 
54% and the speciﬁcity 57%. The sensitivity of umbilical vein maximum 
ﬂow velocity for severe anemia before intrauterine transfusion was 67% 
and the speciﬁcity 57%.
Conclusions: An acute large increase of the fetal hematocrit signiﬁcantly 
decreases middle cerebral artery peak ﬂow velocity. The effect on umbilical 
vein maximum velocity is, however, unpredictable.
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Introduction
Middle cerebral artery peak velocity (MCA peak) and umbilical venous 
maximum velocity (UV max) increase in fetuses when anemia develops.1–7 
Measurements of arterial and venous ﬂow velocities have even been 
described as sensitive indicators of the degree of fetal anemia in red cell 
alloimmunization.3-7 As such, these measurements have recently been 
proposed as an alternative diagnostic method to invasive procedures 
like amniocentesis and cordocentesis.3-7 A lowered blood viscosity due 
to a decrease in hematocrit is an obvious explanation for raised blood 
velocities in anemia. However, ﬂow velocities are inﬂuenced by many other 
factors, and normal values change during gestation: in uncomplicated 
pregnancies, the MCA peak increases from 23 cm/s at 18 weeks to 58 
cm/s at 38 weeks5, and the UV max increases from 15 cm/s at 18 weeks to 
24 cm/s at 38 week.3,8 Arterial ﬂow velocities depend on blood viscosity, 
cardiac output, vessel diameter, and peripheral resistance.9,10 Venous ﬂow 
velocities depend on blood viscosity, vessel diameter, right atrial pressure, 
and ductus venosus function. 
We wanted to study the effects of acute changes in hematocrit on fetal 
maximum blood ﬂow velocities. Therefore, we measured the hematocrit 
before and after intrauterine transfusion (IUT), and MCA peak and UV 
max before, immediately after, and the day after transfusion.
Methods
Setting and Patients
The Leiden University Medical Center is the national referral center for 
the treatment of fetal anemia in the Netherlands. Our methods for 
diagnosis and treatment of severe fetal alloimmune anemia have been 
described previously.11 Between November 2000 and August 2001, Doppler 
ultrasound was performed before, immediately after, and 1 day after all 
IUTs. The study was approved by the institutional review board, and all 
women gave oral informed consent. Fetal blood sampling was performed 
either at the intrahepatic vein or at the placental cord insertion (at the 
CHAPTER 5 |  Effect of transfusion on fetal blood velocities
56
discretion of the operator), and packed red cells with a hematocrit of 
around 80% were given intravenously. Before the procedure, meperidine 
(75 mg), promethazine (25 mg) and indomethacin (50 mg) were given to 
the mother. Atracurium (0.4 mg/kg) was given to the fetus immediately 
after the initial blood sample was taken. 
Measurements
MCA peak and UV max measurements were performed before IUT (0-6 h), 
immediately after (within 30 min) and the day after (12-24 h). All Doppler 
measurements were performed with the angle between the ultrasound 
beam and the direction of the blood ﬂow as close to 0° as possible 
and never exceeding 30°. If the angle was > 0°, an angle correction was 
applied. Flow velocity waveforms were obtained in the absence of fetal 
breathing and body movements. Doppler studies were done by one of 
ﬁve experienced operators (E.S., K.T., R.H.M., F.K., F.V.) using an Acuson 
Sequoia (Acuson, Mountain View, CA) ultrasound machine with a 6.0 
MHz probe. The circle of Willis was visualized and the middle cerebral 
artery was examined close to its origin from the internal carotid artery. In 
the absence of visible changes in the waveform patterns, we measured for 
at least ﬁve waveforms. The highest point of the ﬂow velocity waveform 
(peak systolic velocity) was measured. The UV max was measured in the 
straight intrahepatic portion of the umbilical vein. The maximum velocity 
was measured when a uniform Doppler signal of at least 3 seconds was 
obtained. The hematocrit was measured in the initial fetal blood sample 
and at the end of the transfusion. 
Normal and standardized values
Normal hematological and blood ﬂow velocity values change during 
gestation, and we therefore standardized all measurements (hematocrit, 
MCA peak, and UV max) for gestational age. For fetal hematocrit, we 
used the reference values proposed by Forestier et al.12,13 Standardized fetal 
hematocrit (z_Ht) was deﬁned as the number of SDs that the actual value 
deviated from the normal mean for gestational age. Severe fetal anemia 
was deﬁned as z_Ht ≤ -5, moderate fetal anemia as -2 ≥ z_Ht > -5. For 
MCA peak, we used the reference values proposed by Mari et al.5, and the 
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standardized MCA peak velocity was expressed as multiples of median 
(MoM_MCA) for gestational age. An abnormally increased MCA peak was 
deﬁned as a MoM_MCA ≥ 1.5. For UV max, we used the reference values 
proposed by Oepkes et al.3,8 The standardized UV max velocity (z_UV) 
was deﬁned as the number of SDs the measured value deviated from the 
normal mean for gestational age. An abnormally increased UV max was 
deﬁned as z_UV ≥ 2. Hydrops was classiﬁed as mild when a distinct rim 
of ascites was present with or without pericardial effusion.14 Hydrops 
was classiﬁed as severe when ascites was abundant (free-ﬂoating intra-
abdominal organs) with or without pericardial effusion, skin edema, and 
pleural effusion.14
Statistics
To compare the changes in Doppler velocities (MoM_MCA and z_UV) 
between the three different time points and changes in z_Ht between the 
two different time points, repeated measures analysis of variance was 
used. A value of p < 0.05 was considered signiﬁcant. Comparison between 
subgroups at each time point was performed using t-test (puncture site, 
type of immunization) and ANOVA (presence of hydrops). Comparison 
of the changes between the three different time points in the subgroups 
(according to puncture site, type of immunization and presence of 
hydrops) was done using repeated measures analysis of variance. Because 
of multiple testing, a Bonferoni correction was used for comparison of 
subgroups, and only p-values < 0.01 were considered signiﬁcant.  We 
thereby assumed that z_Ht on the day after transfusion was identical to 
the value obtained immediately after IUT [15]. Sensitivity and speciﬁcity 
of MoM_MCA and z_UV before IUT in the prediction of severe fetal 
anemia were calculated using 2x2 tables. Comparison between sensitivities 
and speciﬁcities of the subgroups (puncture site, type of immunization, 
presence of hydrops, order of IUT) before transfusion was performed using 
χ2 tests. Statistical analysis was performed uing SPSS version 10.0 (SPSS, 
Chiago, IL.).
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Results
During the study period, 80 IUTs were performed in 30 pregnancies. 
Twenty procedures were excluded from analysis because of incomplete 
measurements due to fetal breathing, body movements, or fetal position 
in utero (n=16), or because the ﬁnal fetal blood sample could not 
be obtained (n=3). In 1 case, there was persistent bleeding from the 
puncture site (after the ﬁnal fetal blood sample) and the fetus was found 
to be severely anemic again 7 days later (n=1). Complete measurements 
were obtained from 60 IUTs in 30 fetuses in 29 women (1 with a twin 
pregnancy). Characteristics of these 60 IUTs are shown in Table 1. 
Table 1 - Characteristics of the 60 IUTs
Gestational age (completed weeks), median (range) 29 (19-35)
 
Type of alloimmunization: 
   D 45 (of which 6 mildly hydropic)
   Kell 14 (of which 3 mildly and 3 severely hydropic)
   c  1 
 
Order of IUTs: 
   ﬁrst 22 
   second 15
   third 11
   fourth  7
   ﬁfth  4
   sixth  1
 
Degree of anemia: 
   moderate (-2 SD ≥ Ht > -5 SD) 14
   severe (Ht ≤ - 5 SD) 46
 
Puncture site: 
   placental cord insertion 44
   intrahepatic vein 16
IUT: intra uterine transfusion; Ht: Hematocrit
There were no complications following IUT in our study population. 
The MCA peak decreased immediately after transfusion in 59 of the 60 
cases. There was a rise in UV max immediately after the procedure in 37 of 
the 60 cases. Table 2 shows the mean values (range) of MCA peak, UV max 
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and Ht and their standardized values before, immediately after and 1 day 
after IUT. MCA peak and MoM_MCA as well as UV max and z_UV differed 
signiﬁcantly between the three time points (p<0.0001). Ht and z_Ht 
differed signiﬁcantly between the two time points (p<0.0001). One day 
after IUT, z_UV was signiﬁcantly (p < 0.003) higher in severely hydropic 
fetuses than in mildly hydropic or non-hydropic fetuses. There were no 
other signiﬁcant differences at any of the time points in z_Ht, MoM_MCA, 
and z_UV between the subgroups (according to puncture site, presence 
of hydrops, type of immunization). In addition, there were no signiﬁcant 
difference in the change that occurred after IUT in the subgroups. 
Table 2 - Actual and standardized measurements (mean (range)) before, immediately after and 1 
day after 60 IUTs 
 
    repeated measures
 before IUT after IUT 1 day after IUT ANOVA between
    time points
Actual values    
MCA peak (cm/s) 61.87 (26-109) 32.68 (10-60) 44.40 (18-73) p < 0.0001
UV max (cm/s) 29.72 (15-58) 36.32 (14-101) 22.75 (10-35) p < 0.0001
Ht (l/l) 0.19 (0.04-0.28) 0.40 (0.22-0.47)   p < 0.0001
    
Standardized values    
MoM_MCA 1.59 (0.94-2.68) 0.83 (0.26-1.75) 1.13 (0.67-1.62) p < 0.0001
z_UV  3.09 (-1.38-11.35) 5.19 (-2.6-25.53) 0.87 (-2.92-5.08) p < 0.0001
z_Ht 5.79 (3.13-8.76) 0.43 (-1.79-3.93)  p < 0.0001
IUT: intrauterine transfusion; MCA: Middle cerebral artery; UV: Umbilical vein; Ht: Hematocrit;
MoM_MCA: Multiples of median of MCA for gestational age; z_UV: Number of SDs the actual value 
of UV deviated from normal mean for gestational age; z_Ht: Number of SDs the actual value of Ht 
deviated from normal mean for gestational age
Figure 1 plots hematocrit values of 30 fetuses at 60 IUTs against their 
gestational age. Figure 2 shows the relation between MoM_MCA and z_Ht 
before, immediately after, and 1 day after IUT. A horizontal line is drawn 
at MoM_MCA of 1.5 to separate test-positives (above) from test-negatives 
(below). A vertical line is drawn at the threshold of severe anemia: cases 
on the left of the vertical line were severely anemic, and cases on the 
right were moderately anemic. Figure 3 shows the relation between z_UV 
and z_Ht before, immediately after, and 1 day after IUT. A horizontal 
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line is drawn at z_UV of 2.0 to separate test-positives (above) from test-
negatives (below). A vertical line is again drawn at the threshold of severe 
anemia: cases on the left of the vertical line were severely anemic and 
cases on the right were moderately anemic. As such, Figure 2 and 3 can 
be read as two-by-two tables. Table 3 lists sensitivities and speciﬁcities of 
MoM_MCA and z_UV before IUT in the prediction of severe fetal anemia 
in the study population. There were no signiﬁcant differences in sensitivity 
and speciﬁcity before IUT between subgroups (according to puncture site, 
presence of hydrops, type of immunization, order of IUT).
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Figure 1 - Hematocrit values before 60 intrauterine transfusions (in 30 fetuses), plotted against 
gestational age at blood sampling. The grey zone marks the limits of normal (mean ± 2 SD) fetal 
hematocrit concentrations [13]. The lower line separates moderate (between –2 and -5 SD) from 
severe (≤ –5 SD) fetal anemia. Dark circles represent non-hydropic fetuses, grey circles represent 
mildly hydropic fetuses, and open circles represent severely hydropic fetuses.
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Figure 2 - Relation between standardized middle cerebral artery peak velocity (MoM_MCA) and 
standardized hematocrit (z_Ht) before (squares), immediately after (circles), and 12-24 h after 
(triangles) 60 intrauterine transfusions. Closed symbols represent non-hydropic fetuses, and open 
symbols represent hydropic fetuses. z_Ht was deﬁned as the number of SDs that the actual value 
deviated from the normal mean for gestational age. MoM_MCA was expressed as multiples of 
median for gestational age. The horizontal line drawn at 1.5 MoM_MCA seperates test-positives 
(above) from test-negatives (below). The vertical line drawn at -5 z_Ht is the threshold for severe 
anemia. Cases on the left of the vertical line were severely anemic, cases on the right were non-
anemic or only moderately anemic.
Figure 3 - Relation between standardized umbilical vein maximum velocity (z_UV) and 
standardized hematocrit (z_Ht) before (squares), immediately after (circles), and 12-24 h after 
(triangles) 60 intrauterine transfusions. Closed symbols represent non-hydropic fetuses, and open 
symbols represent hydropic fetuses. z_Ht was deﬁned as the number of SDs that the actual value 
deviated from the normal mean for gestational age. z_UV was deﬁned as the number of SDs the 
measured value deviated from the normal mean for gestational age. The horizontal line drawn at 
2 z_UV seperates test-positives (above) from test-negatives (below). The vertical line drawn at –5 
z_Ht is the threshold for severe anemia. Cases on the left of the vertical line were severely anemic, 
cases on the right were non-anemic or only moderately anemic.
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Discussion
As expected, we found a substantial decrease in MCA peak immediately 
after IUT. Quite unexpectedly, however, we found a steep, though 
temporary, increase in UV max immediately after IUT in 37 of our 60 
cases. The latter ﬁnding challenges the view that the fetal hematocrit is 
the main determinant of the blood ﬂow velocity. Furthermore, sensitivities 
of MCA peak and UV max in the prediction of severe fetal anemia were 
disappointing in our study. There were no signiﬁcant differences in these 
sensitivities between untransfused and previously transfused fetuses.
 
We think that the strength of our study lies in the fact that it resembles 
a laboratory setting: we measured fetal blood ﬂow velocities in the same 
fetus before and after substantially changing its hematocrit. There are, 
however, several shortcomings too. First, we not only changed hematocrit 
during IUT, but also infused a relatively large volume into the fetal vascular 
space. It is known from animal experiments, though, that through loss 
of plasma from the fetal circulation after packed red cell transfusion, 
the fetal blood volume increases by only half of the transfused volume.15 
It is also known from these experiments, that the fetal blood volume 
after IUT remains at the same level for 24 h.15 Second, our standard 
medication before IUT was another factor that, in addition to the changes 
in hematocrit and vascular volume, may have inﬂuenced the fetal response 
to IUT. Third, in individual cases, small hematomas or edemas at the 
Table 3 - Sensitivity and speciﬁcity of MoM_MCA and z_UV before IUT in the prediction of severe 
(Ht ≥ -5 SD) fetal anemia
 total study population untransfused fetuses previously transfused
 (n = 60) (n = 22) fetuses (n = 38)
 MoM_MCA z_UV MoM_MCA z_UV MoM_MCA z_UV
      
Sensitivity % (95% CI) 54 (39-69)  67 (52-80) 58 (33-80) 74 (49-91) 52 (32-71) 63 (42-81)
Speciﬁcity % (95% CI) 57 (29-82) 57 (29-82) 0 (0-71) 33 (1-91) 73 (39-94) 64 (31-89)
MoM_MCA: Multiples of median of MCA for gestational age; z_UV: Number of SDs the actual value of 
UV deviated from normal mean for gestational age; IUT: Intrauterine transfusion; Ht: Hematocrit; 
SD: Standard deviation; 95% CI: 95% Conﬁdence Interval.
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intrahepatic course of the umbilical vein may have inﬂuenced UV max near 
the puncture site. However, we did not ﬁnd a signiﬁcant difference in post 
IUT standardized UV max between procedures according to puncture site.
Mari et al. measured MCA peak before and immediately after IUT in 17 
procedures.10 These authors used no tocolytic agents and did not puncture 
intrahepatically. They found a signiﬁcant decrease in MCA peak following 
IUT. Delle Chiaie et al. measured MCA peak before and after 39 IUTs.2 
They found a signiﬁcant reduction of post transfusion MCA peak values. 
Oepkes measured UV max before and 12 -20 h after the ﬁrst IUT in 36 
fetuses.16 This author found a signiﬁcant decrease in UV max the day after 
IUT. Recently, Stefos et al. measured MCA peak before and immediately 
after 54 procedures.17 They found a decrease in MCA peak in all but 1 
fetus. Our ﬁndings on the effect of IUT on MCA peak and UV max are 
consistent with those of these four studies. The rise in UV max that we 
found immediately after IUT, however, has not been reported previously. 
In an often cited study, Mari et al. have proposed a cut-off value for 
MoM_MCA of 1.5 for moderate anemia, and one of 1.55 for severe 
anemia, as these cutoff values resulted in 100% sensitivity, based on their 
retrospective analysis of 111 fetuses.5 Recently, Detti et al. proposed 
a cutoff value for MoM_MCA of 1.69 for severe anemia in previously 
transfused fetuses, again based on 100% sensitivity in their retrospective 
series of 64 fetuses.18 Delle Chiaie et al. found 73% sensitivity of MCA peak 
before 108 fetal blood samples by using a MCA peak threshold value of 
1.29 multiples of median in the prediction of anemia (Hb ≤ 0.84 MoM).2 
Texeira et al. prospectively studied 26 alloimmunized fetuses and found a 
sensitivity of 67% of an MCA peak of > 2 SD above the mean in predicting 
severe anemia (z_Ht < -4).7 In the present study, we found a sensitivity of 
54% for MCA peak (MoM_MCA ≥ 1.5) in the prediction of severe anemia 
(z_Ht ≤ -5). This may seem disappointing. However, it is well known that 
sensitivities are always lower in prospective series than in the retrospective 
series from which the cut-off values have been derived.
Our study probably raises more questions than that it gives answers. 
First, there was the unexpected rise in UV max immediately after IUT. 
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From this ﬁnding, it seems obvious that the fetal hematocrit is not the 
only and probably not the most important factor determining maximum 
umbilical venous blood ﬂow velocities. The venous pressure may be far 
more important in this matter. Second, the wide range in pre-transfusion 
MoM_MCA for fetuses with identical z_Ht points to the fact that, besides 
hematocrit, other factors such as cardiac output and peripheral resistance 
must play an important role in determining MCA peak. Finally, the protein 
concentration is also a major determinant of blood viscosity.19
In conclusion, an increasing fetal hematocrit has a clear effect on 
maximum arterial and venous ﬂow velocities. This effect is partly the result 
of the changes in blood viscosity, but other factors are certainly involved. 
Given the potential consequences of a false negative result, the sensitivities 
of MCA peak and UV max for severe fetal anemia were disappointing in 
our study. Therefore, monitoring of pregnancies at risk of fetal anemia 
should not rely solely on measuring blood ﬂow velocities. 
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Abstract
Objective: To test the diagnostic accuracy of cardiac ventricular wall 
thickness and cardio-thoracic ratio in the prediction of severe fetal 
alloimmune anemia.
Methods: The thickness of cardiac wall of the left and the right ventricles 
and the inter-ventricular septum were measured in diastole using M-mode 
ultrasound. The cardio-thoracic circumference ratio was measured on the 
B-screen. Reference ranges were obtained in 24 non-immunized control 
pregnancies. The measurements were then obtained in alloimmunized 
fetuses and two by two tables were constructed to compare the frequency 
of abnormal cardiac ultrasound measurements in severe and non-severe 
fetal alloimmune anemia. Ultrasound measurements were considered 
abnormal in case values were > 2 SD above the normal mean for 
gestational age. Severe anemia was deﬁned as a hemoglobin concentration 
of > 5 SD below the normal mean for gestational age.
Results: Complete measurements were obtained in 15 alloimunized fetuses 
with severe anemia and in 16 alloimmunized fetuses without severe 
anemia. Sensitivities of cardiac ultrasound ranged between 0 en 47% and 
speciﬁcities between 77 and 97%.
Conclusion: Diagnostic accuracy of ventricular wall thickness and cardio-
thoracic ratio in the prediction of severe fetal alloimmune anemia was 
disappointing. More than 50% of measurements in severely anemic fetuses 
were within the normal reference ranges. 
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Introduction
Fetal adaptation to chronic anemia includes changes, such as liver and 
spleen enlargement,1-3 and a hyperdynamic circulation.4 One of the signs 
of a hyperdynamic circulation is an increase in the peak systolic velocity of 
the middle cerebral artery. It is widely used as a diagnostic test, because 
peak systolic velocity of the middle cerebral artery is easy to measure and 
quite accurate in predicting severe anemia.5 The hyperdynamic circulation 
is probably caused by a decrease in blood viscosity and by an increase 
in cardiac output. Several authors, did indeed ﬁnd an increased cardiac 
output with the development of anemia in dogs, in fetal lambs and in 
human fetuses.6-9 
We hypothesized that an increase in cardiac output would be 
accompanied by cardiac changes that are visible on ultrasound. In 
addition, our sonographers had the impression that severe anemia 
was accompanied by enlargement of the fetal heart, thickening of the 
ventricular walls and the interventricular septum, and hyperdensity of the 
myocard. Ouzounian et al. measured the biventicular outer dimension in 
alloimmunized patients.10 They found a 50% sensitivity of the biventricular 
outer dimension / biparietal dimension ratio in predicting the necessity of 
neonatal transfusion. Oberhoffer et al. measured cardiac wall thickness 
in fetuses with anemia.11 They found a signiﬁcant increase in cardiac wall 
thickness in anemic fetuses compared to their own reference ranges.
We wanted to test the diagnostic value of cardiac ultrasound in fetal 
alloimmune anemia, and therefore measured cardiac ventricular wall 
thickness and cardio-thoracic ratio in non-anemic, moderately and 
severely anemic alloimmunized fetuses and in non-anemic controls. 
Thus, we hoped to expand our diagnostic possibilities for determining the 
need for fetal transfusion in red cell alloimmunized pregnancies. 
CHAPTER 6 |  Cardiac ventricular wall thickness and cardio-thoracic ratio
70
Methods
Setting and Patients
Leiden University Medical Center is the national referral center for the 
management of fetal hematocytopenias in the Netherlands. Our methods 
for diagnosis and treatment of severe fetal alloimmune anemia have been 
described previously.12 Brieﬂy, patients with high antibody titres (> 1/16) and 
ADCC test > 50 % were followed with weekly ultrasound examinations for 
signs of fetal anemia.13 These signs include hepatosplenomegaly, placental 
thickening, decreased fetal movements, increased maximum ﬂow velocities 
in intrahepatic umbilical vein, increased mean velocity in the descending 
thoracic aorta, increased peak systolic velocity in the middle cerebral 
artery, or incipient hydrops. When severe anemia was suspected at or 
after 27 weeks, (repeated) amniocentesis for Δ OD 450 measurement was 
performed and fetal blood sampling was performed when Δ OD 450 was 
in zone 3 or the upper third of zone 2 and rising.14 In pregnancies before 
27 weeks, the decision to perform the ﬁrst IUT was based on ultrasound 
ﬁndings alone. 
Between March 2001 and May 2002, red cell alloimmunized women 
visiting our center were also followed with detailed fetal cardiac ultrasound. 
Exclusion criteria were: single consultation, and factors prohibiting 
cardiac ultrasound such as abundant fetal breathing or body movements, 
unfavorable fetal position, lack of time to perform the measurements, 
maternal obesity. Additional exclusion criteria were: fetuses negative for 
the offending antigen, hydrops fetalis, no intravascular acces and thus 
hemoglobin concentration unknown at IUT, or no cardiac measurements 
at the time severe anemia was diagnosed. Furthermore, 24 normal controls 
were followed with 4-weekly detailed cardiac ultrasound. The institutional 
review board approved this prospective study, and all women gave oral 
informed consent.
Measurements
Ultrasound measurements were performed at least every two weeks and 0-6 
hours before IUT. M-mode measurements of fetal ventricular wall thickness 
and B-mode cardio-thoracic ratio were obtained in diastole. Ultrasound 
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measurements were both obtained in the absence of fetal breathing and 
body movements by one of two experienced operators 
(ES, KT) using an Acuson Sequoia (Acuson, Mountain View, CA) 
ultrasound machine with a 6.0 MHz probe. Sonographers were blinded 
for fetal hemoglobin measurements but not for Doppler measurements. 
The M-mode cursor was placed in the four-chamber view of the fetal heart 
perpendicular to the interventricular septum, just below the tips of the 
atrioventricular valves. The ventricular wall thickness of the left and the right 
ventricles and of the interventricular septum were then obtained (Figure 1). 
These cardiac wall measurements were only performed when there was no 
doubt about the deﬁnition of endocardial surfaces. 
Figure 1 - Sonographic image of the fetal heart (a) and the orientation of the M-mode cursor, 
placed perpendicular to the interventricular septum, just below the tips of the atrioventricular 
valves. M-Mode measurement (b) in diastole of the left and the right ventricular walls and the 
septum.
LV = left ventricle, RV = right ventricle, RVW = right ventricular wall, LVW = left ventricular wall, 
IVS = inter-ventricular septum
Cardio-thoracic ratios were calculated after measuring the cardiac and 
thoracic circumferences at the level of the four-chamber view of the fetal 
heart (Figure 2). The cardiac circumference was measured on the outmost 
pericard of the heart and the thoracic circumference was measured on the 
outmost of the ribs of the fetus. This technique is slightly different from the 
one described by Paladini et al., who measured thoracic circumference at 
the level of the fetal skin.15 In the alloimmunized patients, fetal hemoglobin 
was measured at the time of fetal blood sampling or in cord blood after 
birth. 
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Normal values
M-mode ventricular wall thickness and cardio-thoracic ratios were also 
measured in 24 uncomplicated pregnancies with normal outcome. 
Each patient was measured ﬁve times with an interval of 4 weeks, between 
18 - 36 weeks by one of two experienced operators (ES, MS). Interobserver 
variability (SD of differences/mean of measurements) for wall thickness 
was 4.2% for the left ventricle, 6.1% for the right ventricle and 8.2% for the 
interventricular septum. Inter-observer limits of agreement (95 % conﬁdence 
interval of differences) were +0.45 to -0.30 mm for ventricular wall thickness 
of the left ventricle and +0.28 to -0.23 mm of the right ventricle and +0.36 
to –0.31 mm of the interventricular septum.16
Statistics
Statistical analyses were performed using SPSS 10.0 (SPSS, Chicago, IL) 
and SAS proc mixed (SAS, Cary, NC). To construct normal references 
ranges, linear mixed models were ﬁtted to the data of the 24 uncomplicated 
pregnancies, assuming a linear relation between the fetal cardiac 
measurements and gestational age with a per person random intercept 
and slope. This yielded an estimate for the mean and standard deviation 
as function of gestational age. Values of > 2 SD above normal mean for 
gestational age were considered as abnormal (positive test result). Severe 
fetal anemia was deﬁned as hemoglobin > 5 SD below the normal mean.17 
Four two by two tables were then created to assess the diagnostic accuracy 
of thickening of the left ventricle, right ventricle, interventricular septum, and 
the cardio-thoracic ratio in the prediction of severe fetal anemia. When there 
was a ﬁrst fetal blood sampling that showed severe fetal anemia, the cardiac 
measurements from immediately before the IUT were used. If there was no 
need for an IUT all the cardiac measurements were used in the analyses. 
Figure 2 - Sonographic image of the fetal 
thorax at the level of the four-chamber view of 
the heart during diastole and the ellipses for 
measuring cardiac and thoracic circumferences. 
The cardiac circumference was measured on the 
outmost pericard of the heart and the thoracic 
circumference was measured on the outmost of 
the ribs of the fetus. 
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Results
The left, right and interventricular septum ventricular wall thickness in 
the 24 normal control fetuses (120 measurements) increased between 17 
and 37 weeks from 1.1 to 4.0, 1.4 to 4.1 and 1.0 to 3.7 mm respectively. 
The cardio-thoracic ratio in these 24 normal fetuses (120 measurements) 
increased between 17 and 37 weeks from 0.52 to 0.55.
During the study period, 81 alloimmunized women where followed in 
our center of which 31 did receive at least one IUT. After exclusion, 15 
severely anemic and 16 moderate or non-anemic fetuses with complete 
measurements remained (Figure 3). Study population characteristics are 
shown in Table 1.
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Figure 3 - Flow-chart of study population with exclusion criteria. After exclusion, 31 fetuses 
remained of which 15 were severely anemic and 16 were moderate or non-anemic.
(1) Because of antigen-negative fetus, low suspicion of anemia, or late referral
(2) Because of lack of time, maternal obesity, fetal breathing or position or body movements
(3) At the time of birth by cesarean section (36 weeks) severe anemia (hemoglobin concentration 7,5 g/dl) was 
diagnosed, whereas the last detailed prenatal cardiac ultrasound had taken place 5 weeks earlier (31 weeks).
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Figure 4 shows reference ranges for left and right cardiac ventricular wall 
and interventricular septum thickness. Figure 5 shows reference ranges 
for cardio-thoracic ratio. Ventricular wall thickness and cardio-thoracic 
ratio of fetuses with and without severe anemia are plotted in these curves. 
Most measurements in alloimmunized pregnancies were within the normal 
reference ranges. 
Table 1 - Patient characteristics
 Contols (n = 24) Alloimmunized Alloimmunized
  pregnancies without pregnancies with
  severe fetal anemia severe fetal anemia
Maternal age 
 (completed years), median (range) 33 (26 - 40) 31 (25 - 40) 31 (25 - 39) 
Gestational age   
 (completed weeks), median (range)
at ﬁrst visit 19 (17 - 21) 20 (13 - 28) 27 (14 - 33)
at birth 40 (36 - 42) 37 (33 - 38) 36 (35 - 37)
at ﬁrst intrauterine transfusion --- --- 31 (17 - 34) 
   
Type of alloimmunization   
   D --- 14 12
   c ---  1  3
   E ---  1 ---
   
Hemoglobin concentration   
before IUT (g/dl), median (range) --- --- 6.0 (3.7 - 9.3)
at birth (g/dl), median (range) --- 12.4 (10.0 - 21.6) ---
   
Number of detailed cardiac 
sonographic measurements 
included in analysis 
median (range) 5 (4-5)  4 (1 - 12) 1
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Figure 4 - Reference ranges for left and right cardiac ventricular wall and interventricular septum 
thickness (mean ± 2 SD). Cardiac ventricular wall thicknesses of fetuses with (black triangles) 
and without (grey circles) severe anemia were plotted in the curves.
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Figure 5 - Reference ranges for cardio-thoracic ratio (mean ± 2 SD). Cardio-thoracic ratios of 
fetuses with (black triangles) and without (grey circles) severe anemia were plotted in the curve.
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Table 2 - Diagnostic accuracy of cardiac wall thickness and cardio-thoracic ratio in the 
prediction of severe fetal anemia in alloimmunized pregnancies.
 Sensitivity Speciﬁcity
Cardiac wall thickness of: 
- left ventricle 0 92.0 %
- septum 0 97.3 %
- right ventricle  40.0 % 77.3 %
Cardio-thoracic ratio 46.7 % 90.4 %
Table 2 lists the sensitivities and speciﬁcities of the different cardiac 
ultrasound measurements in the prediction of severe fetal anemia. All 
sensitivities were below 50%.
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Discussion
We measured the cardiac ventricular wall and interventricular septum 
thickness and the cardio-thoracic ratio in alloimmunized pregnancies 
with and without severe anemia and in non-anemic controls. We found 
that most of these measurements in alloimmunized pregnancies were 
within normal ranges. Their diagnostic accuracy is therefore too low to 
recommend them as a diagnostic tool in predicting severe fetal anemia.  
Other authors have sonographically measured cardiac wall thickness. Alan 
et al. measured cardiac wall thickness in 200 normal fetuses using M-
mode ultrasound.18 They found an increase in left ventricular wall thickness 
from 1.3 to 4.1 mm between 16 and 39 weeks. Sutton et al. measured 
cardiac wall thickness in 16 normal fetuses using M-mode ultrasound.19 
They found a linear increase in left cardiac wall thickness from 2.0 to 3.5 
mm and in right cardiac wall thickness from 2.0 to 3.0 mm between 20 to 
40 weeks. Veille et al. measured cardiac wall thickness in 80 normal fetuses 
with M-mode ultrasound.20 They found an increase in left ventricular wall 
thickness from 1.5 to 3.4 and right ventricular wall thickness from 1.6 to 
3.3 between 17 and 41 weeks. Tan et al. measured cardiac wall thickness 
in 100 normal fetuses.21 They used calipers on B-screen image for their 
measurements. They found an increase in left cardiac wall thickness 
from 1.4 to 3.3 mm and in right cardiac wall thickness from 1.3 to 3.3 
mm between 17 and 37 weeks. Oberhoffer et al. measured cardiac wall 
thickness in 200 normal fetuses using M-mode ultrasound.22 They found 
that the left ventricular wall thickness increased from 1.6 to 3.3 mm, the 
right ventricular wall thickness from 1.6 to 3.7 and the interventricular 
wall thickness from 1.6 to 3.7 mm between 19 and 40 weeks. Our normal 
reference ranges obtained in non-anemic controls are in agreement 
with the results of the ﬁve cited studies. Oberhoffer et al. also measured 
cardiac wall thickness in 30 anemic fetuses and found a symmetrical 
myocardial hypertrophy of the ventricular walls.11 In arround 1/3 of 
their measurements, the interventricular septum thickness was above 
their normal range. In our study, however, the interventricular septum 
thicknesses in anemic fetuses were all within the normal range. 
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Other authors have sonographically measured cardio-thoracic ratio. 
Paladini et al. measured cardio-thoracic circumference ratio in 410 
normal fetuses with gestational ages between 17 weeks and term.15 They 
found a fairly constant circumference ratio throughout pregnancy, with 
a slight increase from 0.45 at 17 weeks to 0.50 at term. Respondec et al. 
measured cardio-thoracic area ratio in 99 normal fetuses and found this 
area ratio to remain relatively constant from 20 to 38 weeks.23 Further, 
these authors measured the heart/chest antero posterior diameter and this 
measurement was also relatively stable throughout pregnancy. Oberhoffer 
et al. measured cardio-thoracic area ratios in 30 fetuses with anemia but 
they found that an increased cardio-thoracic ratio was not a consistent 
ﬁnding in this population.11 Ouzounian et al. measured the biventricular 
outer dimension in diastole with M-mode in 63 alloimmunized patients 
without IUT.10 They stated that this measurement is not ideal as a 
screening method or as a method of surveillance in the management of 
alloimmunized pregnancies. In our study, the slight increase in cardio-
thoracic ratio in normal fetuses throughout pregnancy was similar to that 
in the cited studies. However, we found that the cardio-thoracic ratio was 
within the normal range in 8 of 15 severely anemic fetuses. 
The strength of the present study is that we longitudinally studied cardiac 
wall thickness on both sides of the heart and cardio-thoracic ratio in 
a relatively large number of non-hydropic anemic fetuses. A weakness 
of our study is that the reproducability of M-mode measurements in 
the fetus has been described as poor.24 However, Oberhoffer et al., 
found an intraobserver variability of cardiac wall thickness of ≤ 5.4%.11 
Tan et al. found an interobserver variability of 7%.21 Veille et al. found 
an interobserver variability of ≤ 4.5%.20 In our study, we found an 
interobserver variability of ≤ 8.2%. Another weakness is that we have not 
measured hemoglobin concentration during the pregnancy of fetuses with 
moderate anemia at birth. However, we think that it is very unlikely that a 
neonate with moderate anemia at birth has had periods of severe anemia 
due to alloimmunisation earlier in pregnancy. 
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In conclusion, we hypothesised that an increase in cardiac output in 
severe anemia would be accompanied by cardiac changes that are visible 
on ultrasound. These subjective signs included cardiac wall thickness, 
enlargement of the fetal heart and hyperdensity of the cardiac walls. 
However, we found no clear effect of severe fetal anemia on either M-mode 
measured cardiac ventricular wall thickness or B-mode measured cardio-
thoracic ratio. Therefore, we think these measurements are not helpful in 
the diagnosis of severe fetal alloimmune anemia. 
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Abstract 
Objective: To evaluate the effect of fetal anemia and intrauterine 
transfusion on ventricular shortening fraction. 
Methods: Intrauterine transfusion was performed at a median gestational 
age of 31 weeks (range 19-35). Median hemoglobin concentration before 
and after intrauterine transfusion was 7.9 g/dl (range 2.7-13.7) and 14.3 
g/dl (range 12.7-16.1) respectively. The end-diastolic and end-systolic 
transverse dimensions of the left and right ventricles were obtained using 
M-mode ultrasound. The shortening fractions of both ventricles were 
calculated at three time points: before, immediately after and one day 
after intrauterine transfusion. The blood volume given at intrauterine 
transfusion was expressed as a percentage of estimated fetoplacental 
blood volume.
Results: Complete measurements were obtained from 49 transfusions in 
23 fetuses. Both, left and right, ventricular shortening fractions differed 
signiﬁcantly between the three time points. Left ventricular shortening 
fraction decreased immediately after transfusion in 43 (88 %) of the 49 
fetuses. Right ventricular shortening fraction decreased immediately 
after transfusion in 42 (86 %) of the 49 fetuses. At the ﬁrst intrauterine 
transfusion, there was only a weak correlation between the decrease 
in shortening fraction of both ventricles and the transfused volume 
(left: R2 = 0.15; p = 0.20 / right: R2 = 0.005; p = 0.81).
Conclusion: Transfusion signiﬁcantly decreases the shortening fraction 
of both ventricles of the fetal heart. There is, however, little correlation 
between the decrease in shortening fraction and the volume of red cells 
given at intra-uterine transfusion. 
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Introduction 
A variety of sonographic measurements can be used to describe 
fetal cardiac function. These include morphological measurements, 
such as the cardio thoracic ratio1, dynamic measurements, such as 
ventricular shortening fraction measured in the four-chamber view as 
transverse ventricular diameter2-4 ventricular length5, or area6, Doppler 
measurements, such as isovolumetric contraction time 7, and combined 
measurements such as stroke volume or cardiac output.2 Fetal anemia, 
as well as intrauterine transfusion (IUT), is supposed to have an effect on 
fetal cardiac contractility. 
Previous studies have focused on functional8-11, morphological12, 
Doppler13-17 or combined measurements9; 10; 18; 19 In this study, we have 
chosen to evaluate ventricular shortening fraction in severely anemic 
fetuses before and after IUT. M-mode measured four-chamber view 
transverse shortening fraction probably corresponds best with the 
visual impression of cardiac contractility on a B-mode image. A further 
advantage of ventricular shortening fraction is that it has been shown to 
be fairly constant throughout normal pregnancy.2-4 
We wanted to investigate the possible use of ventricular shortening 
fraction as a diagnostic tool in the diagnosis of fetal anemia and in the 
assessment of cardiac overload during IUT. Our hypothesis for this study 
was that fetal anemia increases and that intra-uterine transusion decreases 
the fetal cardiac contractility. To test this hypothesis, we measured the 
left and right ventricular shortening fractionsin a group of alloimmune 
anemic fetuses before intra-uterine transfuion, immediately after (within 
30 minutes) and a day after IUT.
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Methods
Setting and Patients
Leiden University Medical Center is the national referral center for the 
treatment of fetal anemia in the Netherlands. Our methods for diagnosis 
and treatment of severe fetal alloimmune anemia have been described 
previously.20 Between March 2001 and May 2002, M-mode ultrasound of 
the fetal heart was performed before, immediately after, and one day after 
all IUTs. The institutional review board gave approval for this prospective 
study, and all women gave oral informed consent. Severe fetal anemia was 
deﬁned as hemoglobin-deﬁcit ≥ 5 SD, moderate fetal anemia as 2 SD ≤ 
hemoglobin-deﬁcit < 5 SD, and absence of anemia as hemoglobin-deﬁcit 
< 2 SD of the normal mean.21 Hydrops was classiﬁed as mild when a 
distinct rim of ascites was present with or without pericardial effusion.22 
Hydrops was classiﬁed as severe when ascites was abundant (free-ﬂoating 
intra-abdominal organs) with or without pericardial effusion, skin edema, 
or pleural effusion.22
Procedures
Fetal blood sampling was performed, and packed red cells with a 
hematocrit of 76-84% were given intravenously. The volume given at IUT 
depended on gestational age and on the severity of anemia. Hemoglobin 
was measured in the initial fetal blood sample of the transfusion. The 
hemoglobin concentration target after IUT was 14 g/dl. The transfused 
volume was expressed as a percentage of the estimated fetoplacental 
blood volume (FBV): (transfused volume at IUT / estimated FBV) *100. 
To calculate estimated FBV, we used estimated fetal weight determined 
by ultrasound, together with the assumption of a FBV of 100 ml/kg.23 
Before the procedure, meperidine (75 mg), promethazine (25 mg) and 
indomethacin (50 mg) were given to the mother. Atracurium (0.4 mg/
kg) was given to the fetus immediately after the initial blood sample was 
taken. 
Measurements
M-mode measurements were performed before IUT (0-6 hours), 
immediately after (within ½ hour), and one day after (12-24 hours). In the 
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four-chamber view of the fetal heart, the cursor was placed perpendicular 
to the interventricular septum, just below the tips of the atrioventricular 
valves. The end-diastolic dimension (EDD) and the end-systolic dimension 
(ESD) of the left and the right ventricles were then obtained (Figure 1). 
M-mode measurements were obtained in the absence of fetal breathing 
and body movements. M-mode studies were done by one of two 
experienced operators (ES, KT) using an Acuson Sequoia (Acuson, 
Mountain View, CA) ultrasound machine with a 6.0 MHz probe. The left 
ventricular shortening fraction (LVSF) and the right ventricular shortening 
fraction (RVSF) were calculated using the following formula: shortening 
fraction = (EDD – ESD) / EDD. The percentage decrease between 
shortening fraction before and that after transfusion was calculated as 
(1 – (shortening fraction after IUT / shortening fraction before IUT)) * 100. 
The percentage decrease in shortening fraction was correlated with the 
transfused volume as a percentage of estimated FBV. 
Normal values
LVSF and RVSF were measured in 13 uncomplicated pregnancies with 
normal outcome. Each patient was measured ﬁve times with an interval 
of 4 weeks, between 18 - 36 weeks gestation. Inter-observer limits of 
agreement (95 % conﬁdence interval of differences) for LVSF and RVSF 
were -0.014 to +0.024 and -0.023 to +0.023 respectively.24
Figure 1 - Fetal heart (a) and the orientation of the M-mode cursor, placed perpendicular to the 
interventricular septum, just below the tips of the atrioventricular valves.
M-Mode measurement (b) of the systolic and diastolic transverse ventricular diameters. 
LV = left ventricle, RV = right ventricle, EDD = end-diastolic dimension, ESD = end-systolic dimension
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Statistics
To compare the changes in shortening fraction between the three time 
points in patients with the ﬁrst IUT and in patients with the following IUT, 
a linear mixed model with random effect was used.25 This model was also 
used to compare means between controls and patients, to correct for the 
fact that several measurements per person were performed. Pearson R2 
values were calculated between percentage decrease in shortening fraction 
at ﬁrst IUT and transfused volume as a percentage of estimated FBV. 
Statistical analysis was performed using SPSS 10.0 (SPSS, Chicago, IL) 
and SAS proc mixed (SAS, Cary, NC). A value of p < 0.05 was considered 
signiﬁcant.
Results
During the study period, 85 IUTs were performed in 30 pregnancies. 
Thirty-six procedures were excluded from analysis, because of incomplete 
measurements due to fetal breathing, body movements or fetal position in 
utero (n=23), lack of time to perform the measurements (n=8), maternal 
obesity (n=4), or because intravascular access was not obtained and 
intraperitoneal transfusion was performed (n=1). Complete measurements 
were obtained from 49 IUTs in 23 fetuses in 23 women. Study population 
characteristics are shown in Table 1. There were no major complications 
following IUT in our study population. Minor complications occurred in 
4 IUTs: fetal bradycardia for less than 1 minute (n=2), bleeding from the 
puncture site for less than 3 minutes (n=2).
Figure 2 shows mean (± 2 SEM) LVSF and RVSF in normal (control) fetuses 
(these measurements were longitudinally obtained) as well as in anemic 
fetuses before the ﬁrst IUT, immediately after the ﬁrst IUT, and one day 
after the ﬁrst IUT. Ventricular shortening fraction was higher in anemic 
(ﬁrst IUT) than in normal fetuses but his difference was not statistically 
signiﬁcant (LVSF p=0.280, RVSF p=0.075). Mean (± 2 SEM) LVSF was 0.27 
(0.24-0.29) in normal (control) fetuses. For the 13 fetuses that received 
their ﬁrst transfusion, mean LVSF was 0.30 (0.24-0.35) before IUT, 0.19 
(0.16-0.23) immediately after IUT, and 0.30 (0.26-0.34) one day after IUT 
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(Figure 2). Mean (± 2 SEM) RVSF was 0.21 (0.18-0.25) in normal (control) 
fetuses. For the 13 fetuses that received their ﬁrst transfusion, mean RVSF 
was 0.27 (0.23-0.32) before IUT, 0.16 (0.11-0.22) immediately after IUT, 
and 0.23 (0.18-0.27) one day after IUT (Figure 2). In previously transfused 
fetuses, similar changes were observed: LVSF was 0.28 (0.26-0.31) before 
IUT, 0.22 (0.18-0.25) immediately after IUT, and 0.33 (0.30-0.35) one 
day after IUT. RVSF was 0.31 (0.28-0.35) before IUT, 0.18 (0.14-0.23) 
immediately after IUT, and 0.23 (0.20-0.26) one day after IUT. Mean fetal 
heart rate (± 2 SEM) was 138 (136-140) in normal fetuses, 139 (133-144) 
Table 1 - Characteristics of the 49 IUTs.
Maternal age (completed years), median (range) 32 (19-43)
Gestational age (completed weeks), median (range) 31 (19-35)
Type of alloimmunization 
   D 41 
   Kell  3 
   c  5
Hydrops 
   none 43
   mild  3 (3 D alloimmunizations)
   severe  3 (1 D and 2 Kell alloimmunizations)
Order of IUTs 
   ﬁrst 13
   second 15
   third 11
   fourth  5
   ﬁfth  4
   sixth  1
Infused volume  
   infused volume (ml), median (range) 71 (14-114)
   infused volume/estimated FBV (%), median (range) 44 (14-85)
Hemoglobin 
   hemoglobin before IUT (g/dl), median (range) 7.9 (2.7 – 13.7)
   hemoglobin after IUT (g/dl), median (range), (n = 47) 14.3 (12.7 – 16.1) 
Degree of anemia 
   none (Hb > -2 SD)  1
   moderate (-2 SD ≥ Hb > -5 SD) 11
   severe (Hb ≤ - 5 SD) 37
IUT = intra-uterine transfusion, FBV = fetoplacental blood volume, Hb = Hemoglobin, SD = standard deviation
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Figure 2 - Shortening fraction (mean ± 2 SEM) of the left (LVSF) and the right (RVSF) ventricle 
in 13 normal controls (taken in account that the measurements are longitudinally obtained with 
according change in SEM), and in 13 anemic fetuses before, immediately after, and one day after 
the ﬁrst IUT. Ventricular shortening fraction was higher in anemic than in normal fetuses but this 
difference was not statistically signiﬁcant. In anemic fetuses, LVSF and RVSF differed signiﬁcantly 
between the three time points (p<0.001).  
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in anemic fetuses before the ﬁrst IUT, 133 (126-139) immediately after the 
ﬁrst IUT, and 141 (138-145) one day after the ﬁrst IUT. In anemic fetuses 
LVSF and RVSF, as well as fetal heart rate, differed signiﬁcantly between 
the three time points. This applied to fetuses receiving the ﬁrst transfusion 
as well as for previously transfused fetuses (p<0.004).
Figure 3 shows the relation between ventricular shortening fraction before 
and immediately after IUT. The 45-degree line divides the fetuses with a 
decrease in shortening fraction from the fetuses with an increase. LVSF 
decreased in 43/49 (88 %) of IUTs, RVSF decreased in 42/49 (86 %) of 
IUTs. Hydropic fetuses showed a similar pattern as non-hydropic fetuses, 
although there was a tendency towards higher shortening fractions in 
hydropic fetuses. 
Figure 3 - Relation between 
ventricular shortening 
fractions before and 
immediately after IUT (49 
IUTs in 23 fetuses). Each 
dot represents the two 
ventricular shortening 
fractions concerning one 
IUT, the value before IUT is 
on the x-axis and the post-
transfusion value is on the 
y-axis. (A) Diagram for the 
left ventricular shortening 
fraction (LVSF) and (B) for 
right ventricular shortening 
fraction (RVSF). 
The 45º line divides the 
fetuses with a decrease 
in shortening fraction 
(right of the line) from the 
fetuses with an increase in 
shortening fraction (left 
of the line). Black circles 
represent non-hydropic 
fetuses, grey circles represent 
mildly hydropic fetuses, 
and open circles represent 
severely hydropic fetuses. 
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Figure 4 shows the relation between percentage decrease in shortening 
fraction during transfusion and the transfused volume as a percentage 
of estimated FBV in 49 IUTs. We found only weak correlations for this 
relation at the ﬁrst IUT (left: R2 = 0.15; p= 0.20 / right: R2 =0.005; P = 0.1.
Figure 4 - Relation between change in shortening fraction and transfused volume in 49 IUTs. 
The change in shortening fractions is expressed as a percentage of the pre-transfusion value 
(minus value for decrease and plus value for increase). The percentage decrease in shortening 
fraction during transfusion was calculated as (1 – (shortening fraction after IUT / shortening 
fraction before IUT)) * 100. The transfused volume is expressed as a percentage of estimated 
fetoplacental blood volume (FBV). Transfused volume was calculated as: (transfused volume at 
IUT / estimated FBV) *100. Black circles represent non-hydropic fetuses, grey circles represent 
mildly hydropic fetuses, and open circles represent severely hydropic fetuses. 
(A) Diagram for effect on left ventricular shortening fraction (LVSF) and (B) for right ventricular 
shortening fraction (RVSF). 
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Discussion
We measured LVSF and RVSF in normal fetuses and in anemic fetuses 
before and after IUT. We found that both LVSF and RVSF were higher 
in anemic than in normal fetuses, though this was not statistically 
signiﬁcant. Fetal heart rate signiﬁcantly decreased immediately after 
IUT. Furthermore, we found a substantial and statistically signiﬁcant 
decrease in both LVSF and RVSF immediately after IUT. One would expect 
shortening fraction to decrease more after the administration of relatively 
large volumes of packed red cells. However, we found only a very weak 
correlation between the decrease in shortening fraction and the transfused 
volume (as a percentage of estimated FBV).
 
A review of normal LVSF and RVSF values as measured by different 
researchers is presented in Table 2.2-4; 26; 27 Some researchers found a small 
decrease in ventricular shortening fraction with advancing gestational 
age; most researchers, however, found no signiﬁcant effect of gestational 
age. As shown in Table 2, mean LVSF and RVSF are, in different research 
papers, close to 33%, ranging between 0.26 to 0.48 for the left ventricle 
and 0.21 to 0.42 for the right ventricle. We do not have an explanation 
Table 2 - Literature review of reference values for ventricular shortening fraction measured by 
M-mode in normal fetuses.
First author,  year Range of Number  Number Mean Mean
 gestational of of LVSF RVSF
 age (weeks) fetuses measurements (SD) (SD) 
    
Wladimiroff et al,27 (1981) 27-33 27 27 0.29 (0.07) 0.29 (0.06)
 34-40 26 26 0.26 (0.06) 0.26 (0.06)
De Vore et al,3 (1984) 18-41 82 82 0.33 (0.04) 0.32 (0.04)
Koyanagi et al,26 (1990) 18-41 104 104 0.26 (0.02) 0.29 (0.02)
Agata et al,2 (1991) 37-40 34 34 0.34 (0.06) ---
Hsieh et al,4 (2000) 10-40 42 241 0.48 (0.13) 0.42 (0.11)
Present study 18-36 13 65 0.27 (0.08) 0.21 (0.10)
Weighted mean of above 
mentioned studies --- 328 --- 0.32 (0.06) 0.31 (0.06)
LVSF = left ventricular shortening fraction, RVSF = right ventricular shortening fraction, 
SD = standard deviation
CHAPTER 7 |  Cardiac contractility in fetal anemia
92
for the differing range of normal values in previous studies, other than 
the difference between imaging techniques and the position within the 
ventricle from where the measurements are taken.3 In our study mean 
LVSF was 0.27 and RVSF 0.21. These normal values are rather low in 
comparison to most of those in the studies listed in Table 2. Therefore, we 
suggest that sonographers should create their own reference ranges for 
ventricular shortening fraction.
 
We think that the strength of our study lies in the fact that we measured 
the shortening fraction on both sides of the heart in the same fetus 
before and after changing its FBV. This change was substantial in most 
cases. Further, we measured a relatively large number of fetuses with 
severe anemia. There are also some weaknesses in our study. First, the 
repeatability of M-mode measurements in the fetus has been described 
as poor.28 However, in 1990, Veille et al. assessed the error of the cursor 
placement and found that there was no statistical difference between 
measurements of the right and the left ventricle at two different levels (at 
the tips of the atrioventricular valves and at the insertions of the valves) 
either during diastole or during systole.29 Therefore the placement of the 
M-mode cursor at the atrioventricular valves in ventricular shortening 
fraction measurements is less critical than would be expected. Further, 
inter-observer variability in M-mode ventricular shortening fraction was 
measured by two groups of researchers.27;29 They found a measuring 
error of 5%. Inter-observer limits of agreement in our study were 
–0.014 to +0.024 for LVSF and –0.023 to +0.023 for RVSF. Second, our 
standard medication before IUT included indomethacin. In some fetuses 
indomethacin causes transient constriction of the ductus arteriosus, 
even after short-term use.30 This may have inﬂuenced LVSF and RVSF 
after IUT. Indeed, in 1997, Harada et al. showed that administration of 
indomethacin decreased the right ventricular area shortening fraction, but 
not the left ventricular area shortening fraction.31 
 
Other authors have reported on cardiac function before and after 
intrauterine transfusion. Their ﬁndings are summarized in Table 3. In 
short, cardiac output decreased immediately after IUT whereas measures 
of afterload increased immediately after IUT.8-11; 14; 16; 17; 19 Twelve hours 
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Table 3 - Summary of results of previous studies on cardiac function before and after intrauterine 
transfusion.
 No. No.
Authors, of of Measure of Immediate effect Effect of IUT
year fetuses IUTs cardiac function of IUT after > 12 hours
Copel et al,13 24 64 Umbilical artery, pulsatility index  no change in the
1988   Descending aorta, pulsatility index  pulsatility index for
     any of the vessels
Copel et al,18 11 11 Left ventricular output   no signiﬁcant changes
1989   Right ventricular output  no signiﬁcant changes
Weiner et al,11  8 20 Umbilical venous pressure increase with 4.2 mmHg
1989    
Mari et al,15  16 16 Middle cerebral artery, pulsatile index  no signiﬁcant 
1990   Internal carotid artery, pulsatility index  difference in the
   Anterior cerebral artery, pulsatility index  pulsatility index for
   Thoracic aorta, pulsatility index  any of the vessels
   Abdominal aorta, pulsatility index
   Renal artery, pulsatility index 
   Femoral artery, pulsatility index
   Umbilical artery, pulsatility index
   Heartrate  no change in heartrate
Mari et al,16  13 13 Middle cerebral artery, pulsatilel index decrease with 0.70 decrease with 0.01 
1990   Internal carotid artery, decrease with 0.57 decrease with 0.10
   Anterior cerebral artery, pulsatility index decrease with 0.69 decrease with 0.08
   Umbilical artery, pulsatility index decrease with 0.29 decrease with 0.05
   Heartrate signiﬁcant increase no signiﬁcant changes
    in heartrate
Moise et al,10  21 38 Umbilical venous pressure increase with 1.7 mm Hg
1990   Left ventricular output decrease with 19% 
   Right ventricular output decrease with 22%
   Heartrate no change in heartrate
Rizzo et al,19 12 12 Left ventricular output decrease with 63.84  
1990    ml/min/kg   
   Right ventricular output decrease with 52.35 
    ml/min/kg
   Heartrate no signiﬁcant changes
Oepkes et al,17 21 21 Ductus venosus peak velocity increase with 0.26 m/s decrease with 0.09 m/s
1993   no signiﬁcant changes decrease with 0.09 m/s
   
d’ Ancona et al,14  14 14 Portal vein Increase with 0.7 of the
1997     H/L ratio
Goodrum et al,8 21 27 Mean umbilical arterial pressure increase with 4.6 mm Hg
1997   Heartrate bradycardia in 5/16 IUTs 
Kilby et al,9  6  6 Left ventricular afterload increase with 7.2 mm Hg/ml
1998 fetal  End-diastolic pressure increase with 6.5 mm Hg
 lambs  End-diastolic vollume increase with 0.9 ml/kg
   Left ventricular output decrease with 28 ml/kg/min
   Heartrate no signiﬁcant changes
This study 23 49 Left ventricular shortening fraction decrease from 0.30 to 0.19 no signiﬁcant decrease
   Right ventricular shortening fraction decrease from 0.27 to 0.16 no signiﬁcant decrease
   Heartrate signiﬁcant decrease no signiﬁcant decreasE
   
H/L ratio, ratio between high (peak)  and low (nadir) velocities in the portal vein
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after IUT, however, these changes were no longer demonstrable.13; 15;18 Our 
ﬁndings, that VSF decreased immediately after IUT and normalized within 
12 hours are, thus, in accordance with the ﬁndings of these previous 
studies. Further, we have related the change in VSF with the relative 
increase in blood volume during IUT. However, we found only a weak 
correlation.
In 1999 Ulm et al. described two pregnancies in the same woman where 
they performed 11 and 13 transfusions respectively.32 In their case report, 
they suggest that continuation of intravascular therapy until term may 
represent a reasonable alternative to selective premature delivery even in 
cases with highly aggressive maternal rhesus alloimmunization. Our study 
suggests that a smaller number of IUTs but with a larger volume do not 
endanger the condition of the fetal heart. Massive IUT (a mean of 45% of 
FPV in 15 minutes) was well tolerated in our study. Although we perform 
IUT from 16 weeks' gestation onwards and aim at term delivery, the 
maximum number of IUT per pregnancy in our clinic has been 7 with low 
overall mortality and morbidity.22
 
In anemic fetuses middle cerebral artery peak velocity is increased.33 After 
IUT this peak velocity of the middle cerebral artery decreases.34 It has been 
suggested that fetal hematocrit as well as left ventricular contractility are 
the main determining factors for these changes in middle cerebral artery 
peak velocity.35; 36 Our ﬁnding of a decreased LVSF after IUT supports the 
suggestion that decreased cardiac contractility contributes to the decrease 
in middle cerebral artery peak velocity after IUT.
In conclusion, fetal anemia had only a minor effect on M-mode measured 
shortening fraction of the left and right ventricles of the heart. Intrauterine 
transfusion, on the other hand, had a clear effect, with both LVSF and 
RVSF decreasing signiﬁcantly. This corresponds well with the visual 
impression of decreased contractility on B-mode ultrasound during and 
immediately after IUT. This effect on contractility showed, however, little 
correlation with the transfused volume given at IUT.
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The studies (chapters 2 to 7) in this thesis concern diagnostic methods that 
are used to differentiate between moderate and severe anemia in red cell 
alloimmunization. In this thesis, severe fetal anemia is deﬁned as ≥ 5 SD 
below the normal mean for gestation, because then anemia will become 
life-threatening and, thus, in need of therapy. Moderate fetal anemia is 
deﬁned as > 2 SD but < 5 SD below the normal mean for gestation. Only 
a small percentage of pregnancies with red-cell antagonism is at risk 
for severe anemia. In the Netherlands, there are approximately 200,000 
pregnancies >16 weeks yearly, around 4000 of these mothers have irregular 
red-cell antibodies, but only around 100 pregnancies are at risk for severe 
anemia. It is of great importance that the diagnosis of severe fetal anemia 
is made not too late because of the risk of fetal demise but also not too 
early, because of the risk and disadvantages of unnecessary cordocenteses 
and intrauterine transfusions. 
In the Netherlands, pregnant women have a screening test for antibodies 
against red blood cells in the ﬁrst trimester. In pregnant women with 
irregular antibodies, there will be a risk selection on the basis of obstetric 
history and antibody titers.1 Pregnancies at risk for moderate to severe 
fetal anemia will be referred to the national center for intrauterine 
treatment, the Leiden University Medical Center (LUMC). At each visit, 
distinction between moderate (leading to continued close monitoring) 
and severe (leading to immediately intrauterine treatment) fetal anemia 
has to be made. This distinction will be preferably made by non-
invasive methods: maternal perception of fetal movements and different 
ultrasonographic measurements (B-mode, M-mode and Doppler). Invasive 
diagnostics methods (amniocentesis, cordocentesis) will only be used 
when non-invasive methods indicate severe anemia. 
The research questions in this thesis were:
1. What is the basis of the relation between decreased concentration of 
red cells in fetal blood and increased bilirubin concentration in amniotic 
ﬂuid? 
2. What is the basis of the relation between decreased concentration of 
red cells in fetal blood and increased peak systolic velocity in the middle 
cerebral artery?
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3. Which one of these two measurements (bilirubin concentration in 
amniotic ﬂuid or middle cerebral artery peak systolic velocity) provides 
the better differentiation between moderate and severe anemia? 
4. Are certain ultrasonographic measurements of the fetal heart useful in 
the diagnosis of severe fetal anemia?
As a result of the studies in this thesis, the following answers can now be 
formulated and discussed:
1. Increased destruction of red blood cells caused by alloimmunization 
leads to an increased concentration of unconjugated bilirubin in fetal 
blood. This unconjugated bilirubin is liposoluble and crosses the placenta 
through the transmembranous pathway along the concentration gradient 
between fetal and maternal blood. In normal pregnancies, mean maternal 
serum bilirubin concentration is 0.35 mg/dl2, and mean fetal serum 
bilirubin concentration is 1.5 mg/dl.3 In case of red cell destruction in 
alloimmunization, fetal serum bilirubin concentration is in the range of 2 
to 12 mg/dl.4 In addition to this clearance of unconjugated bilirubin from 
fetal blood into maternal blood, there must also be a pathway through 
which, during periods with high concentration of bilirubin in fetal blood, 
small amounts of bilirubin are “leaking” into the amniotic ﬂuid. 
By measuring the amniotic ﬂuid/fetal blood ratio of bilirubin at 
different gestational ages and comparing these with the amniotic 
ﬂuid/fetal blood ratio of albumin as found in the literature, we found, 
in a speculative study, indirect evidence (chapter 4) for the following 
hypothesis. Unconjugated bilirubin is almost completely bound to 
albumin in fetal blood as well as in amniotic ﬂuid. Through a small 
fraction of unbound unconjugated bilirubin that crosses liposoluble 
membranes, an equilibrium is established whereby bilirubin will evenly 
spread over the available albumin. On the basis of our measurements, we 
provide indirect evidence for this assumption. Following our hypothesis, 
the bilirubin concentration in amniotic ﬂuid is, thus, deﬁned by the 
bilirubin concentration in fetal blood (which is increased in case of 
fetal anemia) and by the amniotic ﬂuid /fetal blood ratio of albumin 
(which is decreasing with increasing gestational age). In a more recent 
(yet unpublished) study we have measured bilirubin and albumin 
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concentrations simultaneously in fetal blood and in amniotic ﬂuid. The 
ﬁndings in this unpublished study are consistent with our hypothesis. 
What does this hypothesis mean for the physiology of fetal bilirubin? 
Which pathway does bilirubin take to enter the amniotic ﬂuid? Among 
ﬁve possible pathways bilirubin could take to build up a concentration 
in amniotic ﬂuid (fetal kidneys, lungs, skin, bowel, membranes) the 
consequence of our ﬁndings is that the membranes seem the only 
remaining pathway. Our argumentation is the following. Both in fetal 
blood and amniotic ﬂuid the bilirubin is, to a large, extent unconjugated. 
Unconjugated bilirubin is for around 99% tightly bound to albumin. It is 
highly improbable that urine or alveolar ﬂuid contributes substantially to 
the bilirubin concentration in amniotic ﬂuid. While protein concentrations 
in these bodily ﬂuids are 100 to 200 times lower than those in fetal 
plasma, whereas protein concentration in amniotic ﬂuid is only 10 to 
20 times lower than in fetal plasma. Because of the very low albumin 
concentrations in urine and alveolar ﬂuid, these ﬂuids must act as a 
barrier for unconjugated bilirubin leaving the plasma and entering the 
amniotic ﬂuid compartment. A meconial origin of amniotic ﬂuid bilirubin 
is inconsistent with a clinically relevant correlation between amniotic ﬂuid 
and fetal blood bilirubin concentration. The fetal skin probably does serve 
as a major pathway for solute and water exchange, including unconjugated 
bilirubin, between fetus and amniotic ﬂuid, but only until 16 weeks 
of gestation. However, in fetuses of 25 weeks, the fetal skin is already 
completely keratinized. The fetal membranes, on the other hand, retain a 
high permeability until term. Therefore, bilirubin exchange between fetal 
blood and amniotic ﬂuid most probably occur through this pathway, 
called intra-membranous pathway. 
An intriguing question, raised after the previous discussion on how 
bilirubin enters the amniotic ﬂuid, is: how does albumin enter the amniotic 
ﬂuid. And is this albumin of maternal or of fetal origin? This question 
is the subject of a new study protocol. Characterization of albumin is, 
however, difﬁcult. On the basis of studies performed in the seventies, there 
are reasons to believe that the albumin in amniotic ﬂuid is of maternal 
origin. It is supposed that maternal albumin passes from maternal blood 
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to amniotic ﬂuid through the transmembraneous pathway. Among 
others, this would mean that a fetus, drinking large amounts of amniotic 
ﬂuid every day, digests maternal proteins already before birth. As a 
consequence, lactation starts, so to speak, already in utero.  
The more we learn about fetal physiology, the more we discover that 
the fetus is already very well prepared for extra uterine life. The changes 
that occur at birth are somewhat less radical than previously believed. 
In the beginning of the 19th century, Kergaradec5 demonstrated the fetal 
heartbeat. In the ﬁrst half of the 20th century, Ahlfeld discovered that the 
fetus was breathing in utero6. With these breathing movements, probably 
triggered by pCO
2
 increase in fetal brain stem cells, the fetus is aspirating 
oxygen-containing blood from the placenta through the umbilical cord 
vein, ductus venosus and left ventricle of the heart. The extra amount of 
oxygen-rich blood thus reaches the fetal brain within seconds after the 
start of “breathing”. In the second half of the 20th century, it was proved 
that the fetal blood pH is identical to that in adults.7 In the beginning 
of the 21st century, it may now be shown that a fetus receives motherly 
albumin as nutritional supplement. During the 3rd trimester, drinking of 
amniotic ﬂuid contributes for approximately 10% of the daily necessary 
calorie and amino-acid intake, as has been shown in fetuses with 
obstructions of the gastrointestinal tract.8;9
2. Theoretically, the systolic blood ﬂow velocity in the middle cerebral 
artery may be increased because of a
a. decrease in hematocrit, resulting in a lowered viscosity of fetal blood. 
b. increase of fetal heart contractility as an adaptation to anemia
c. decrease of peripheral vascular resistance in the brain vessels because of 
a decrease of intracellular pO
2
.
Our studies (chapter 5 and 7) provide arguments for the fact that, in 
anemia, a decrease of blood viscosity is not the only factor leading to 
an increase of middle cerebral artery peak systolic velocity. Probably, 
the contractility of the heart is a second important factor. However, our 
studies show some weaknesses. First, there is the fact that our Doppler 
measurements were performed during an intrauterine transfusion 
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whereby the mother receives medication. Amongst others, she receives 
the prostaglandin synthesis inhibitor indomethacine that affects 
the fetal circulation because it leads to a constriction of the ductus 
arteriosus. These changes in the fetal circulation may have inﬂuenced our 
measurements. Furthermore, during intrauterine treatment, the blood 
stream in the umbilical vein is affected by the therapeutic administration 
of blood in this vein. For the purpose of intrauterine transfusion, umbilical 
vein puncture was performed at the placental umbilical cord insertion or 
in the pars intrahepatica. A small hematoma in the Warthons gelly, or a 
contraction of the capsule of Glisson in the liver, will inﬂuence local and 
systemic hemodynamics. This may, again, have inﬂuenced our Doppler 
measurements.
3. Knowledge about the physiological changes in relation to hemolytic 
anemia can help in the understanding of diagnostic methods. Many 
clinicians, however, are only interested in knowing which method, 
amniocentesis with measurement of bilirubin concentration in amniotic 
ﬂuid, or Doppler with measurement of the middle cerebral artery systolic 
peak velocity is better in predicting fetal anemia. The studies in chapters 
2 and 3 are addressing this question. In chapter 2 we have performed a 
systematic review of publications on sensitivity and speciﬁcity of Δ OD 450 
and peak systolic velocity of MCA. On the one hand, this study provides 
us with a reasonable impression of the quality of both tests. But on the 
other hand, this study cannot be conclusive. First, there is only one (small) 
prospective study in this review. Second, different deﬁnitions of anemia 
were used in different studies, which makes comparison and metanalysis 
impossible. Third, almost all the studies on Δ OD 450 were performed in 
a different time period than the MCA studies. Anyhow, it is evident that 
the range of sensitivities and speciﬁcities of the Δ OD 450 and the middle 
cerebral artery systolic peak velocity are overlapping. In chapter 3, we have 
measured the accuracy of amniotic ﬂuid Δ OD 450 values in the prediction 
of severe fetal anemia in D-alloimmunization in a prospective, non-
controlled study. We found that in Liley’s extrapolated curve, zone 3 plus 
the upper third of zone 2 had a sensitivity of 97% and an overall accuracy 
of 86% for severe non-hydropic fetal anemia. This excellent clinical 
accuracy is, however, rather surprising. First, there is the fact that 
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Δ OD 450 has obviously no relation with compensatory hematopoiesis. 
Second, the clinical performance of the Δ OD 450 test is in contrast 
with the poor correlation between Δ OD 450 and fetal hemoglobin 
concentration. Our conclusion is that Liley’s chart is a rather rough 
method. It gives clinically useful information regarding the necessity of IUT, 
but is a poor predictor of the actual hemoglobin concentration. 
Between 2000 and 2004 we have been involved in an international 
multicenter study. In this so called Diamond study, invasive amniocenteses 
and non-invasive Doppler, two tests for the prediction of fetal anemia 
were performed simultaneously in the same patients and compared with 
the gold standard, fetal hemoglobin concentration. The main results of 
the Diamond study have been presented as an abstract,10 and the paper 
has meanwhile been submitted for publication. In the Diamond study, 
sensitivity of middle cerebral artery systolic peak velocity is around 85% 
and that of Δ OD 450 measurement is around 75%. This difference in 
sensitivity was signiﬁcant. Thus, MCA is certainly not inferior to Δ OD 450. 
Moreover, its non-invasiveness is an undisputable advantage. Therefore, 
middle cerebral artery systolic peak velocity measurements probably 
will become the diagnostic method of choice and Δ OD 450 a second 
line method, used only in cases where the non-invasive methods are not 
conclusive. 
4. In this thesis, B mode and M-mode (chapter 6 and 7) ultrasound 
measurements of the fetal heart have been shown to be disappointing 
in predicting fetal anemia. These measurements seem to add little or 
nothing to the diagnosis of fetal anemia. There is, however, a measurable 
effect of IUT on cardiac contractility. In chapter 7, we describe that cardiac 
contractility is signiﬁcantly decreased after IUT. This corroborates the 
visual impression on ultrasound. 
In chapter 6, cardiac ventricular wall thickness and cardio-thoracic ratio in 
relation to fetal anemia are described. Most measurements in fetuses of 
alloimmunized pregnancies where within normal ranges. Their diagnostic 
accuracy is therefore too low to recommend them as a tool in predicting 
severe anemia. A remaining ultrasound item in cases of severe early fetal 
anemia, is the subjective impression of increased density of the cardiac walls. 
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We think a few topics deserve attention in future research: the echogenic 
density of the cardiac walls but also of the fetal bowel and skin (pre-
hydropic changes) could be such a topic. In addition, intra uterine 
transfusion provides an ideal opportunity to study the changes in blood 
volume and blood constituents in fetal anemia and during intrauterine 
treatment. Very few centers in the world have sufﬁcient numbers of 
patients as the LUMC does, to study these changes. Therefore, the LUMC 
has an obligation to continue to perform studies in this ﬁeld. 
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Introduction (chapter 1)
Before or during pregnancy, the mother, who types negative for a speciﬁc 
red cell antigen, might develop antibodies against the offending antigen. 
This so-called alloimmunization can occur after a blood transfusion, after 
organ transplantation or after a fetomaternal transfusion. The maternal 
antibodies can pass through the placenta into the fetal circulation. In case 
the fetus is positive for the antigen, the red cells will be destructed and 
anemia may develop. In serious cases this can lead to massive hydrops and 
ultimately to intrauterine death. In the Netherlands, there are annually 
approximately 200 pregnancies in which potentially dangerous maternal 
antibodies against fetal erythrocytes are diagnosed (mainly anti-D, anti-c 
and anti-K antibodies). Pregnant women with a high concentration of such 
antibodies are at high risk for fetal complications. In approximately 30% 
of these high-risk pregnancies intrauterine transfusion is warranted. Severe 
fetal anemia can already occur at 16 weeks of gestation. 
Diagnostic procedures are focussed on timely detecting severe fetal 
anemia, before hydrops or death occur. Early recognition and treatment 
of fetal anemia before hydrops fetalis develops, leads to a better 
outcome. However, treatment of a fetus in utero that has only moderate 
anemia carries several risks, such as procedure-related fetal loss rates, 
boostering of existing antibodies and the development of new antibodies. 
In differentiating between moderate and severe fetal anemia, several 
techniques are used. A ﬁrst diagnostic tool is the history of the woman. 
The obstetrical history is a part of this anamnesis. Important is also 
the perception of fetal movements by the mother. A reduction of the 
fetal movements felt by the mother is an alarming signal and raises the 
suspicion of severe fetal anemia. The second diagnostic technique is to 
follow the concentration of maternal antibodies. When these are rising, 
the fetus may be in danger for anemia. The third diagnostic technique is 
measurement of bilirubin concentration in amniotic ﬂuid. This method 
was described by Liley in 1961 and is based on the increase of optical 
density at a wavelength of 450 nanometres, the Δ OD 450. A fourth 
diagnostic technique is ultrasonography. On a B-mode image, discrete 
sign of hydrops can be seen. Fetal organs involved in the production 
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and destruction of red cells, such as liver and spleen, can be measured. 
These organs are often enlarged in severe anemia. Placental thickness 
can also be measured. With M-mode ultrasound, some measurements 
can be performed more accurately. With Doppler, the blood velocity in 
the fetal arteries and veins can be measured. A ﬁfth diagnostic technique 
is cardiotocography. The fetal heart frequency is measured for 30 to 45 
minutes. This technique is, however, inappropriate for diagnosing fetal 
anemia, because, even in very severe anemia, there is most often a normal 
pattern of the fetal heart frequency. A ﬁnal diagnostic technique is fetal 
cordocentesis. At cordocentesis the exact hemoglobin concentration can 
be measured. However, the risk of severe complications for the fetus at 
cordocentesis is approximately 2 or 3 %. 
In this thesis, the link between severe fetal anemia and on the one hand, 
the bilirubin concentration and on the other hand, some more recently 
used ultrasonographic measurements are studied. The treatment of 
fetal anemia is symptomatic and is aimed at keeping the fetus in a good 
condition by intrauterine transfusion until term thus avoiding life-
threatening fetal anemia and iatrogenic prematurity at the same time.
 
The aim of the different studies in this thesis was to analyse the physiology 
of fetal anemia and the evaluation of diagnostic techniques to predict the 
optimal timing for fetal blood transfusion. 
This thesis contains two parts: the chemical approach and the 
ultrasonographic approach.
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Part 1: Chemical approach
The chemical techniques are based on the fact that destruction of fetal 
hemoglobin will increase the bilirubin concentration of amniotic ﬂuid. 
Amniotic ﬂuid is obtained by amniocenteses. The degree of yellowness of 
the amniotic ﬂuid will be measured as described by William Liley in 1961. 
This yellowness is caused exclusively by bilirubin. 
First, a systematic literature review was performed (chapter 2) on the 
diagnostic accuracy of bilirubin measurement in amniotic ﬂuid and of 
middle cerebral artery peak systolic velocity in the prediction of severe fetal 
alloimmune anemia. The advantage of Doppler measurements is their non-
invasiveness. The conclusion of this review, based on mainly retrospective 
studies, was that the sensitivity for both techniques is variable but quite 
similar. In case of equal sensitivity, it seems clear that the non-invasive 
technique is preferable. A new large multicenter study in which both 
techniques are prospectively tested in the same patients has meanwhile 
been performed. 
In chapter 3 we studied how accurately the bilirubin concentration in 
amniotic ﬂuid predicts severe fetal anemia in the second and third 
trimester in D-alloimmunized pregnancies. Seventy-nine non-hydropic 
singleton pregnancies were included where amniocentesis was performed 
within 4 days of ﬁrst fetal blood sampling. Amniotic ﬂuid Δ OD 450 values 
were plotted on a Liley’s chart. In 1961 William Liley described a chart with 
on the x-as gestational age and on the y-as the Δ OD 450. In this chart, 3 
zones were deﬁned: zone 1 (non-anemic), zone 2 (moderate anemia) and 
zone 3 (severe anemia). The original Liley chart is from 27 to 36 weeks, the 
extrapolated Liley curve extends from 18 to 36 weeks. Accuracy, sensitivity 
and speciﬁcity were calculated for two commonly used cut-off levels on 
the Liley chart. Sensitivity of Δ OD 450 values in Liley’s zone 3 or the 
upper third of Liley’s zone 2 was 95% before and 98% after 27 weeks. We 
concluded that Liley’s extrapolated curve predicts severe fetal anemia with 
high sensitivity and reasonable speciﬁcity. 
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In chapter 4 we investigated the pathways of bilirubin from fetal blood 
to amniotic ﬂuid. Therefore, we studied the relation between bilirubin 
concentration in blood and in amniotic ﬂuid in 68 non-hydropic rhesus 
D-alloimmunized anemic fetuses at ﬁrst intrauterine transfusion. In 
these alloimmunized fetuses, the amniotic ﬂuid/fetal blood ratio for 
bilirubin decreased from 0.09 at 28 weeks to 0.05 at 33 weeks. In normal, 
non-anemic fetussen, amniotic ﬂuid/fetal blood ratios for bilirubin, 
and for albumin, are in the same range and show a similar decrease 
during gestation. On the basis of these ﬁndings, we hypothesised that 
amniotic ﬂuid bilirubin concentration is determined, ﬁrstly, by fetal blood 
concentration and, secondly, by the amniotic ﬂuid/fetal blood ratio of 
albumin. 
Among ﬁve possible pathways bilirubin could take to build up a 
concentration in amniotic ﬂuid (fetal kidneys, lungs, skin, bowel, 
membranes), the intramembranous pathway appears to be the only 
remaining possibility. During fetal life, bilirubin in amniotic ﬂuid is mainly 
unconjugated. Unconjugated bilirubin is bound to albumin almost 
completely. It is very improbable, therefore, that urine or alveolar ﬂuid 
contribute substantially to the bilirubin concentration in amniotic ﬂuid, 
because the albumin concentration in these body ﬂuids is 100 to 200 
times lower than in fetal plasma. The albumin concentration in amniotic 
ﬂuid on the other hand, is only 10 to 20 times lower than in fetal plasma. 
Because of the very low albumin concentrations in urine and alveolar ﬂuid, 
these ﬂuids act as a barrier for unconjugated bilirubin leaving the plasma 
and entering the amniotic ﬂuid compartment. A meconium origin of 
amniotic ﬂuid bilirubin is inconsistent with a clinically relevant correlation 
between amniotic ﬂuid and fetal blood bilirubin concentration. The fetal 
skin probably serves as a major pathway for solute and water exchange, 
including unconjugated bilirubin, between amniotic ﬂuid and fetus till 
16 weeks of gestation. In fetuses of more than 25 weeks, however, the 
fetal skin is completely keratinized. The fetal membranes, on the other 
hand, retain a high permeability until term. Therefore, bilirubin exchange 
between fetal blood and amniotic ﬂuid most probably occurs through the 
intramembraneous pathway.  
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Part 2: Ultrasonographic approach
Since 1995 several publications have shown that middle cerebral artery 
blood velocities during systole of the fetal heart are increased in case 
of fetal anemia. It is still unclear if this increased blood ﬂow velocity in 
anemia is the result of changes in blood viscosity, in contractility of the 
heart or in peripheral brain resistance. 
In order to study the effect of blood viscosity on the systolic blood 
ﬂow velocities in the middle cerebral artery, blood ﬂow velocities were 
measured before and after intrauterine transfusion. After all blood 
viscosity increases during intrauterine transfusion. In chapter 5 we describe 
the effect of a large increase of the heamatocrit on middle cerebral artery 
peak and umbilical vein maximum velocities in anemic fetuses. Therefore, 
middle cerebral artery peak ﬂow velocities and umbilical vein maximum 
ﬂow velocities were measured before, immediately after and 12-24 hours 
after 60 intrauterine transfusion. The middle cerebral artery peak ﬂow 
velocity decreased immediately after transfusion in 59 of the 60 cases. 
There was a rise in umbilical vein maximum ﬂow velocity immediately 
after intrauterine transfusion in 37 of the 60 cases. The conclusion was 
that an acute large increase of the fetal hematocrit signiﬁcantly decreases 
middle cerebral artery peak ﬂow velocity. The effect on umbilical vein 
maximum velocity was, however, unpredictable. The fact that the umbilical 
vein maximum ﬂow velocity in several cases increases after intrauterine 
transfusion is of course in contradiction with the saying that the viscosity 
of fetal blood is the most important factor determining blood ﬂow 
velocity. Also the wide range in arterial blood ﬂow velocities in fetuses with 
the same hematocrit points to the fact that, besides hematocrit, other 
factors such as cardiac output and peripheral resistance must play an 
important role. 
In chapter 6 we studied the diagnostic accuracy of cardiac ventricular 
wall thickness and cardio-thoracic ratio in the prediction of severe fetal 
anemia. The thickness of cardiac wall of the left and the right ventricle 
and the inter-ventricular septum were measured in diastole using M-mode 
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ultrasound. The cardio-thoracic circumference ratio was measured on 
the B-screen. The measurements were obtained in alloimmunized fetuses. 
Then, two by two tables were constructed to compare the frequency of 
abnormal cardiac ultrasound measurements in severe and non-severe 
fetal alloimmune anemia. Complete measurements were obtained in 15 
alloimmunized fetuses with severe anemia and in 16 alloimmunized fetuses 
without severe anemia. Sensitivities of cardiac ultrasound ranged between 
0 and 47% and speciﬁcities between 77 and 97%. The conclusion was that 
diagnostic accuracy of ventricular wall thickness and cardio-thoracic ratio 
in the prediction of severe fetal alloimmune anemia was disappointing. 
More than 50% of measurements in severely anemic fetuses were within the 
normal reference ranges.  
In chapter 7, we evaluated the effect of fetal anemia and intrauterine 
transfusion on ventricular shortening fraction. During systole, the 
ventricles of the heart decrease in size. The procentual decrease in size 
of the ventricles during systole can be measured with ultrasound and 
expressed as ventricular shortening fraction. The end-diastolic and end-
systolic transverse dimensions of the left and the right ventricles were 
obtained in 23 fetuses before and after 49 intrauterine transfusions. 
The blood volume given at intrauterine transfusion was expressed as 
a percentage of estimated fetoplacental blood volume. Shortening 
fractions of the left and right ventricles differed signiﬁcantly between 
three time points: before, immediately after and one day after intrauterine 
transfusion. Left ventricular shortening fraction decreased immediately 
after transfusion in 43 (88%) of the 49 procedures. Right ventricular 
shortening fraction decreased immediately after transfusion in 42 (86%) 
of the 49 procedures. At the ﬁrst intrauterine transfusion, there appeared 
to be only a weak correlation between the decrease in shortening fraction 
of both ventricles and the transfused volume. The conclusion was that 
transfusion signiﬁcantly decreases the shortening fraction of both 
ventricles of the fetal heart. There is, however, little correlation between 
the decrease in shortening fraction and the volume of red cells given at 
intrauterine transfusion.
117
We hope that the different studies in this thesis will contribute to 
improved understanding of the physiologic changes in fetal anemia and 
thus to a less invasive and timely diagnosis of severe fetal anemia. Finally, 
the studies described in this thesis leads to an improved insight into the 
hemodynamic changes, during and after treatment with intrauterine 
transfusion. 

Samenvatting

Inleiding (hoofdstuk 1)
Voor of tijdens de zwangerschap kunnen bij de moeder antistoffen 
ontstaan tegen rhesus D en andere rode bloedcel antigenen. Deze 
immunisatie kan veroorzaakt worden door bloedtransfusie, door 
orgaantransplantatie of door foetomaternale transfusie. De antistoffen 
die de moeder maakt en die gericht zijn tegen de antigenen op de foetale 
rode bloedcellen kunnen de placenta passeren. Door antigen gemedieerde 
destructie van rode bloedcellen kan foetale anemie ontstaan. Deze anemie 
kan in ernstige gevallen leiden tot massale hydrops en uiteindelijk tot 
het intra-uterien overlijden van de foetus. In Nederland zijn er jaarlijks 
ongeveer 200 zwangeren met potentiëel gevaarlijke antistoffen. Het gaat 
hierbij voornamelijk om anti-D, anti-c en anti-K antistoffen. Bij de helft 
van deze zwangeren is de concentratie aan antistoffen zo hoog dat men 
spreekt van ernstige immunisatie. Bij ongeveer 30% van de vrouwen met 
ernstige immunisatie krijgt de foetus een dusdanig ernstige anemie dat een 
intra-uteriene transfusie noodzakelijk is. Deze ernstige foetale anemie kan 
al optreden bij een zwangerschapsduur van 16 weken. 
De diagnostiek is gericht op het tijdig opsporen van ernstige foetale 
anemie, dus vóór er hydrops of sterfte ontstaat. Uit onderzoek is gebleken 
dat tijdige detectie en behandeling van foetale anemie, voor hydrops 
ontstaat, leidt tot betere uitkomsten voor het kind. Anderzijds is het 
riskant en minder zinvol om een foetus met slechts matige anemie in de 
baarmoeder te behandelen. Tijdig opsporen betekent dus niet alleen 
niet te laat, maar ook niet te vroeg. Bij de differentiatie tussen matige en 
ernstige foetale anemie wordt gebruik gemaakt van een aantal technieken. 
Voor tijdige detectie zijn in de loop van jaren diverse diagnostische 
technieken ontwikkeld. Een eerste diagnostische techniek is de anamnese 
van de vrouw. Hierbij speelt de obstetrische voorgeschiedenis een rol. 
Belangrijk is ook het voelen bewegen van het ongeboren kind, het “leven 
voelen”. Verminderen van leven voelen is een alarmsignaal en geeft hoge 
verdenking op ernstige foetale anemie. Een tweede diagnostische techniek 
is het vervolgen van de concentratie aan moederlijke antistoffen. Zodra 
deze stijgt loopt de foetus meer gevaar. Een derde diagnostische techniek 
is de meting van de bilirubine concentratie in vruchtwater. Deze methode 
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is in 1961 door Liley beschreven en wordt ook wel meting van de toename 
van de optische dichtheid bij een golﬂengte van 450 nanometer, de 
Δ OD 450 genoemd. Een vierde diagnostische techniek is echoscopisch 
onderzoek. Met behulp van echoscopie kunnen de eerste tekenen van 
hydrops gezien worden. Tevens kunnen foetale organen die met bloed 
aanmaak of -afbraak te maken hebben, zoals lever en milt, gemeten 
worden. Deze organen zijn vaak vergroot bij ernstige anemie. Ook kan de 
placenta dikte gemeten worden. Met de echoscopische M-mode kunnen 
metingen aan het hart nauwkeurig verricht worden. En met Doppler kan de 
bloedstroomsnelheid in de foetale arteriën en venen gemeten worden. Een 
vijfde diagnostische techniek is cardiotocograﬁe. Hierbij wordt de foetale 
hartfrequentie over 30 tot 45 minuten geregistreerd. Deze techniek is 
echter van betrekkelijke waarde, aangezien bij ernstige anemie een normaal 
hartfrequentie patroon kan voorkomen. Een laatste diagnostiche techniek 
is de navelstrengpunctie. Bij een navelstrengpunctie kan de mate van 
anemie exact gemeten worden. Het risico op ernstige complicaties voor de 
foetus bedraagt bij een navelstrengpunctie echter 2 à 3%. 
Het verband tussen ernstige foetale anemie en enerzijds de bilirubine 
concentratie in vruchtwater en anderzijds een aantal meer recent toegepaste 
echoscopische metingen vormen het onderwerp van dit proefschrift. De 
behandeling van foetale anemie is symptomatisch en is er op gericht de 
foetus met bloedtransfusies in goede conditie te houden tot de à terme 
periode. Vermeden wordt aldus dat een kind geboren wordt met naast zijn 
anemisch probleem tevens problemen van (iatrogene) vroeggeboorte.
 
Het doel van de verschillende studies in dit proefschrift was meer inzicht 
te krijgen in de foetale fysiologie bij anemie en de evaluatie van een aantal 
diagnostische methoden voor het voorspellen van het optimale moment 
voor foetale bloedtransfusie. Dit proefschrift bestaat uit twee delen: de 
chemische benadering en de echoscopische benadering.
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Deel 1: Chemische benadering
De chemische techniek voor de diagnostiek van foetale anemie is gebaseerd 
op het feit dat bij afbraak van het foetale hemoglobine de bilirubine 
concentratie in het vruchtwater zal toenemen. Vruchtwater wordt 
verkregen door middel van amniocentese. De mate van geelverkleuring 
van het vruchtwater wordt vervolgens gemeten zoals in 1961 door William 
Liley beschreven. Deze geelverkleuring wordt uitsluitend veroorzaakt door 
bilirubine. 
Allereerst werd een overzicht gemaakt (hoofdstuk 2) van de literatuur over 
de waarde van bilirubine metingen in vruchtwater en tevens van Doppler 
van de arteria cerebri media in de voorspelling van ernstige foetale 
alloimmune anemie. Het voordeel van de Doppler methode is dat het een 
non-invasieve manier is om anemie te voorspellen. De conclusie van deze 
review is dat de sensitiviteit voor beide technieken in onderzoeken, die voor 
het grootste deel retrospectief zijn, varieert maar grosso modo overeen 
komt. Bij gelijk blijvende sensitiviteit dient de vraag gesteld te worden of de 
niet invasieve techniek dan niet vanzelf als de betere gezien moet worden. 
Een prospectief en groter onderzoek waarbij beide technieken in dezelfde 
patiënten worden uitgevoerd moet uitsluitsel gaan geven. 
In hoofdstuk 3 werd onderzocht hoe accuraat de bilirubine concentratie 
in vruchtwater ernstige foetale anemie voorspelt in het tweede en derde 
trimester van de zwangerschap. Hiervoor werden 79 niet-hydropische 
eenling zwangerschappen met een D immunisatie geincludeerd waarbij een 
amniocentese was verricht maximaal 4 dagen voor de eerste intra-uteriene 
transfusie. De Δ OD 450 waarden uit het vruchtwater werden in een Liley 
graﬁek geplaatst. William Liley beschreef in 1961 een graﬁek met op de 
x-as de zwangerschapsduur en op de y-as de Δ OD 450. In deze graﬁek 
zijn 3 zones getekend: zone 1 (geen anemie), zone 2 (matige anemie) en 
zone 3 (ernstige anemie). De originele graﬁek van Liley gaat vanaf 27 tot 
36 weken, bij de geëxtrapoleerde Liley curve is deze curve doorgetrokken 
van 27 naar 18 weken. Sensitiviteit en speciﬁciteit werden berekend voor 
de meest gangbare afkappunten op de Liley curve. De sensitiviteit voor de 
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bovenste 2/3 van Liley zone 2 was 95% vóór 27 weken en 98% na 27 weken. 
Geconcludeerd werd dat de geëxtrapoleerde Liley curve met zeer goede 
sensitiviteit en redelijke speciﬁciteit ernstige anemie voorspelt. 
In hoofdstuk 4 wordt gezocht naar de weg waarlangs de verhoogde 
concentratie aan bilirubine in het foetale bloed leidt tot een verhoogde 
concentratie aan bilirubine in vruchtwater. Hiervoor werd de relatie 
onderzocht tussen bilirubine concentratie in foetaal bloed en deze in 
vruchtwater bij 68 rhesus D allo-geimmuniseerde foetus met anemie 
zonder hydrops bij de eerste intra-uteriene transfusie. Bij deze anemische 
foetussen verminderde de vruchtwater/foetale bloed ratio van bilirubine 
van 0.09 bij 28 weken naar 0.05 bij 33 weken. In normale, niet anemische 
foetussen, zijn de vruchtwater/foetale bloed ratio voor bilirubine en 
voor albumine in dezelfde range en laten dezelfde afname zien tijdens de 
zwangerschap. Op basis van deze bevindingen hebben wij de hypothese 
geformuleerd dat de bilirubine concentratie in vruchtwater word bepaald 
door ten eerste de foetale bloed bilirubine concentratie en ten tweede door 
de vruchtwater/foetale bloed ratio van albumine. 
Van de vijf mogelijke wegen die bilirubine kan nemen om vanuit foetaal 
bloed in het vruchtwater een concentratie op te bouwen (foetale nieren, 
longen, huid, darmen en vliezen) lijken de vliezen de meest voor de hand 
liggende. Tijdens het foetale leven is bilirubine in vruchtwater voor het 
grootste deel ongeconjugeerd. Ongeconjugeerd bilirubine is voor 99% 
gebonden aan albumine. Het is onwaarschijnlijk dat bilirubine in het 
vruchtwater komt via foetale urine of longvocht omdat de albumine 
concentratie in deze lichaamsvochten 100 tot 200 maal lager is dan 
in foetaal plasma. De albumine concentratie in vruchtwater is, echter, 
maar 10 tot 20 keer lager dan in foetaal plasma. Wegens de extreem 
lage albumine concentratie in foetale urine en longvocht werken deze 
vloeistoffen als een barrière voor het ongeconjugeerde bilirubine die het 
plasma wil verlaten en het vruchtwater compartiment wil binnengaan. Dat 
foetale ontlasting, meconium genaamd, het bilirubine tussen foetaal bloed 
en vruchtwater zou transporteren is niet in overeenstemming te brengen 
met een klinisch relevante correlatie tussen concentratie van bilirubine 
in vruchtwater en in foetaal bloed. De dunne foetale huid laat tot een 
CHAPTER 6 |  Nederlandse samenvatting
125
zwangerschapsduur van 16 weken waarschijnlijk uitwisseling toe tussen 
bloed en vruchtwater van allerhande stoffen, waaronder ongeconjugeerd 
bilirubine. Bij een zwangerschapsduur van 25 weken is de foetale huid 
echter volledig gekeratiniseerd. De foetale vliezen blijven wel permeabel 
gedurende de gehele zwangerschap. Daarom vindt de uitwisseling 
van ongeconjugeerd bilirubine tussen foetaal bloed en vruchtwater 
hoogstwaarschijnlijk plaats via deze weg. 
Deel 2: Echoscopische benadering
Sinds 1995 is in meerdere publicaties aangetoond dat de stroomsnelheid 
van bloed in de arteria cerebri media tijdens de systole van het hart 
verhoogd is bij foetale anemie. Men kan zich daarbij afvragen of deze 
toegenomen stroomsnelheid bij anemie het gevolg is van veranderingen in 
de viscositeit van het bloed, van de contractie kracht van het hart of van de 
perifere weerstand in de hersenen. 
Om de invloed van de viscositeit op de systolische bloedstroomsnelheden 
in de arteria cerebri media te onderzoeken werd de stroomsnelheid 
gemeten voor en na een intra-uteriene transfusie. Bij een transfusie 
neemt de viscositeit van het bloed immers toe. In hoofdstuk 5 word het 
effect beschreven van een acute grote toename van het hematocrit op de 
piek systolische snelheid in de arteria cerebri media en op de maximum 
snelheid van de vena umbilicalis. Daartoe werden de snelheden in de 
arteria cerebri media en de vena umbilicalis gemeten vóór, direct na en 
de dag na 60 intra-uteriene transfusies. De snelheid in de arteria cerebri 
media verminderde in 59 van de 60 gevallen direct na transfusie. Er was in 
37 van de 60 gevallen een toename van de snelheid in de vena umbilicalis. 
Geconcludeerd werd dat een acute toename van het hematocriet zoals 
bij een intra-uteriene transfusie signiﬁcant de snelheid in de arteria 
cerebri media vermindert. Het effect op de snelheid in de vena umbilicalis 
daarentegen bleek onvoorspelbaar. Het feit dat de stroomsnelheid in 
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de vena umbilicalis in vele gevallen toenam na transfusie is natuurlijk in 
tegenspraak met de stelling dat de viscositeit van bloed de voornaamste 
determinant is van de bloedstroomsnelheid. Ook de uitgebreide variatie 
in arteriële bloedstroomsnelheden bij foetussen met hetzelfde hematocrit 
wijst erop dat, naast hematocrit, andere factoren zoals slagkracht van het 
hart en perifere weerstand een belangrijke rol moeten spelen. 
In hoofdstuk 6 werd uitgezocht wat de diagnostische accuraatheid is van 
metingen van de cardiale ventrikel wand dikte en de cor-thorax ratio om 
ernstige foetale anemie te voorspellen. De dikte van de cardiale ventrikel 
wand van de linker en de rechter ventrikel werden gemeten met behulp 
van M-mode echoscopisch onderzoek. De cor-thorax ratio werd gemeten 
op het B-beeld. De metingen werden verkregen in geïmmuniseerde 
zwangerschappen. Vervolgens werden 2 bij 2 tabellen gemaakt om de 
frequentie van abnormale cardiale echoscopische metingen in ernstige en 
niet-ernstige foetale anemie te vergelijken. De metingen werden verkregen 
bij 15 foetussen met ernstige anemie en bij 16 foetussen zonder ernstige 
anemie. De sensitiviteit van de cardiale echoscopische metingen varieerde 
van 0 tot 47% en de speciﬁciteit van 77 tot 97%. Geconcludeerd werd 
dat de diagnostische waarde van de ventriculaire wand dikte en de cor-
thorax ratio teleurstellend was. Meer dan 50% van de metingen in ernstige 
anemische foetussen was immers binnen de normale referentie waarden 
voor normale foetussen. 
In hoofdstuk 7 werd geëvalueerd wat het effect van foetale anemie en intra-
uteriene transfusie was op de ventriculaire verkortings fractie. Tijdens 
de systole worden de ventrikels van het hart kleiner. Hoeveel kleiner de 
ventrikels tijdens de systole zijn kan met de echo gemeten worden en 
wordt uitgedrukt als de ventriculaire verkortings fractie. Bij 23 foetussen 
werd voor en na 49 transfusies de eind diastolische en eind systolische 
transversale dimensie van de rechter en de linker ventrikel gemeten. Het 
bloed gegeven bij intra-uteriene transfusie werd weergegeven als een 
percentage van het geschatte fetoplacentale bloed volume. Verkortings 
fracties van de rechter en de linker ventrikel verschilden signiﬁcant voor, 
direct na en 1 dag na transfusie. De linker shortening fractie verminderde 
direct na transfusie in 43 van de 49 procedures. De rechter shortening 
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fractie verminderde direct na transfusie in 42 van de 49 procedures. Bij 
de eerste transfusie bleek er maar een matige correlatie te zijn tussen 
het verminderen van de shortening fractie van beide ventrikels en het 
getransfundeerde volume. Er werd geconcludeerd dat intra-uteriene 
transfusie de shortening fractie van beide ventrikels vermindert. Er is echter 
weinig correlatie tussen de vermindering van de shortening fractie en de 
hoeveelheid bloed gegeven tijdens transfusie.
Hopelijk dragen de verschillende studies in dit proefschrift bij aan de 
diagnostiek bij verdenking op foetale anemie en aan een beter inzicht in 
de veranderingen die optreden bij het opheffen van foetale anemie tijdens 
intra-uteriene transfusies. 
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Zonder de vele steun en medewerking van anderen was dit proefschrift 
nooit verschenen. Hiervoor wil ik een aantal mensen graag persoonlijk 
bedanken.
Allereerst het “rhesus team”: gynaecologen, verpleegkundigen en 
echoscopisten voor hun geduld als ik weer eens lang moest meten
rondom een transfusie en natuurlijk voor de gezellige en goede 
samenwerking. 
Robertjan, Katinka en Patricia wil ik bedanken voor het leren van de kunst 
van het echo-en. 
Alle patiënten wil ik bedanken voor hun medewerking en geduld en alle 
medeauteurs voor de goede samenwerking.
De secretaresses van de staf verloskunde, met name Ivanka die het langst 
en meest heeft meegemaakt, wil ik bedanken voor de ondersteuning. 
Veel dank ook aan alle collega agiko’s. De agiko kamer was als een baken 
met eerst Celine en later Elles, Denise, Kim en Marieke om te klagen over 
alles wat me dwars zat en in de loop van de tijd was dat heel wat! Ook de 
agikolunch (met daarbij Henry, Cor, Kitty en iedereen die verder bijschoof) 
met zijn bekende kroket (ik houd helemaal niet van kroketten!!) was altijd 
prima om te spuien.
Buiten het werk zijn er ook veel mensen die mij gesteund hebben de 
afgelopen jaren. Al mijn vrienden, iedereen afzonderlijk op zijn eigen 
manier, ben ik daar heel dankbaar voor.
Mijn ouders wil ik bedanken omdat ze altijd zijn blijven geloven dat, no 
matter what, het goed zou komen met mij en mijn proefschrift! Hiervoor 
heel veel dank. Vava voor zijn liefde, interesse en beschouwende visies, 
Moenie voor haar liefde, steun en praktische oplossingen.
Mijn zussen, broer, zwager en schoonzus wil ik bedanken voor hun 
interesse en steun. Rinneke voor haar lieve zorgzaamheid en advies. 
Cornelie voor alle gezelligheid en haar luisterende oor op elk uur van de 
dag of nacht. Dick voor zijn altijd blinken in afwezigheid en er toch voor 
me zijn. Edwin voor zijn liefde voor Rin en zijn vaderlijke steun. Thu voor 
haar liefde voor Dick en haar steun op afstand.
Janneke, Nico, Mark en Leonie voor de steun, in welke zin ook, en dat is 
in de loop der jaren een heleboel geweest. Paul als goede vader van mijn 
prachtige kinderen en als steun in mijn studietijd en tijdens het begin van 
dit proefschrift.
Als laatste wil ik mijn twee prachtige kinderen, Ivar en Merle bedanken. 
Ivar voor zijn onzachtzinnige liefde, humor en verstrekkende interesse in 
alles van het leven. Wat soms zeer lastige vragen oplevert! Merle voor haar 
lieve liefde, mooie lach, haar warmte en vrolijkheid. En jullie beiden als 
heerlijke aﬂeiding naast het harde werken voor dit proefschrift!
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